By Sebastian Gensior — 10 May 2026

The Weekly Term Sheet (2026-W19)

W19 at a glance

Window: Sun May 3 – Fri May 8, 2026. ~$17.95B committed deal value + up to $5.5B contingent + ~$3.2B fresh biotech equity / structured capital. Headline events: $6.7B Merck/Terns close (Tue); $4.1B Angelini/Catalyst (Thu); $1.05B Roche/PathAI (Thu); $1.0B Phoenix Asia/ACEA all-stock RTO (Mon); $250M RVMD synthetic-royalty 2nd tranche funded (Mon); $250M BXLS/Anagram structured (Thu); $90M Abivax royalty repurchase (Tue); Bizengri full sBLA approval — first-ever drug for NRG1+ cholangiocarcinoma under 7th National Priority Voucher (Fri).

M&A

Deal	Headline	Date
UCB / Candid Therapeutics	$2.0B + up to $200M (autoimmune TCE platform)	Sun 3 May
Phoenix Asia / ACEA Pharma	$1.0B all-stock RTO + $20M convertible note	Mon 4 May
Gyre Therapeutics / Cullgen close	~$300M all-stock (fibrosis + protein degraders / DACs)	Mon 4 May
Lunai Bioworks / Oncotelic (N2B)	$20M preferred + $12.5M Lunai Series B convert preferred to Oncotelic	4–6 May
Merck / Terns close	$53.00/sh = ~$6.7B all-cash (TERN-701 BCR::ABL1)	Tue 5 May
Bayer / Perfuse	$300M up + up to $2.15B = $2.45B (PER-001 ophthalmology)	Wed 6 May
Angelini / Catalyst	$31.50/sh = ~$4.1B all-cash	Thu 7 May
Roche / PathAI	$750M up + up to $300M = $1.05B (digital pathology + CDx)	Thu 7 May

Royalty monetization + structured finance

Deal	Headline	Date
MacroGenics / Sagard ZYNYZ expansion	$60M + up to $20M; aggregate Sagard $130M	Mon 4 May
RPRX / Revolution Medicines 2nd tranche	$250M funded; 4.55% / 2.50% / 1.00% tiered rates	Mon 4 May (10-Q Wed)
Lexicon / Hercules term loan	Up to $100M senior-secured (3 tranches)	Mon 4 May
Orchestra BioMed / Ligand RIPA final tranche	$15M ($35M aggregate Ligand commitment)	Mon 6 May
Abivax royalty certificate repurchase	$90M ($45M cash + $45M ADS)	Tue 5 May
BioPharma Credit / Alphatec prepayment	$37.1M realized; 14.91% gross IRR / 11.93% net IRR	Tue–Wed 5–6 May
Citius Oncology / Avenue	Up to $36.5M debt + warrants	Tue 5 May
Anagram / Blackstone Life Sciences	$250M structured (hybrid equity + royalty)	Thu 7 May

Out-licenses

Deal	Headline	Date
BioCryst / Neopharmed Gentili (navenibart EU)	$345M + 18–30% royalties	Mon 4 May
Cue Biopharma / Ascendant (Ascendant-221)	$15M + up to $676.5M + HSD-LDD tiered royalties	Mon 4 May
Madrigal / Arrowhead (ARO-PNPLA3)	$25M + up to $975M + HSD-mid-teens royalties	Tue 5 May
GSK / SiranBio (SA030)	$55M + up to $1.0B + tiered royalties	Wed 6 May
Halozyme / Oruka (Hypercon ORKA-001)	Upfront + milestones + mid-single-digit royalties	Wed 6 May
MannKind / UTHR (ralinepag DPI expansion)	$5M + $35M + 10% royalty	Wed 6 May
Mirum / Incyte (zilurgisertib worldwide)	$16M + milestones + mid-to-high-single-digit royalties; PDUFA 26 Sep 2026	Wed 6 May
Halozyme / GSK (ENHANZE oncology + ADCs)	Upfront + milestones + royalties; first ENHANZE ADC deal	Thu 7 May
BMS / Lonza (SYNtecan™ ADC linker-payload)	Upfront + milestones + royalties (single target)	Thu 7 May

Late-stage readouts

Asset	Headline	Sponsor
Mirum VISTAS Ph2b PSC	Volixibat 20 mg BID hits primary; NDA 2H 2026	Mirum
Lineage / Roche RG6501	+9 letters BCVA at 36 mo (n=5 sub-cohort)	Lineage / Roche-Genentech
Falk / Renexxion naronapride MOVE-IT	20 mg TID p=0.0046 vs placebo, n=328	Falk / Renexxion
Takeda TAK-881-3001 PID	Recombinant hyaluronidase fSCIg	Takeda
Spur FLT201 (Gaucher)	Bone marrow burden 11→7	Spur (ex-Freeline)
Cytokinetics ACACIA-HCM	Aficamten dual primary KCCQ-CSS + peak VO2 met	Cytokinetics
Viridian REVEAL-2 (chronic TED)	Elegrobart 50% Q4W / 54% Q8W proptosis vs 15% placebo; DRI synthetic royalty counterparty	Viridian
J&J JNJ-4804 Ph2b IBD	IL-23 + TNF-α co-antibody; positive CD + UC; RPRX $500M R&D co-funding	J&J
Avalo AVTX-009 Ph2 HS	Anti-IL-1β; 42.9% HiSCR75; AVTX +18%	Avalo
AIM ImmunoTech Ampligen Ph2 ovarian	50% ORR; 21% CR; mOS 32.5 mo	AIM ImmunoTech
Raynovent ZSP1601 Ph2b MASH	China-origin pan-PDE; 64.9% response rate	Raynovent
Entrada ELEVATE-44 Cohort 1 (DMD)	Positive Cohort 1 data	Entrada
Incyte TRuE-AD4 Ph3b 24-wk Opzelura	84.3% EASI75 maintained at 24 wk	Incyte
Sebela tegoprazan Ph3 erosive esophagitis	P-CAB superiority vs lansoprazole	Sebela
Medicus Pharma SKNJCT-003 Ph2	55% CR @ 200µg in nodular BCC	Medicus Pharma
ISOThrive MHS-1031 Ph2 NERD	Highly stat sig	ISOThrive
MingMed QA102 Ph2 dry AMD	Primary missed; secondaries positive	MingMed

Royalty-vehicle prints (Q1 2026)

Vehicle	Headline	Date
Royalty Pharma (RPRX)	PR $925M (+10%); cap deploy $528M / $1.25B announced; FY guide raised	Wed 6 May
Innoviva	Q1 GSK royalty $55.2M net	Q1 release
Theravance	$50M RPRX milestone received Feb 2026	Q1 release
Ligand	Q1 royalty +56% to $43.0M	Q1 release
Alnylam	Q1 Leqvio royalty +85% to $49.0M	Q1 release
Genmab	Q1 royalty revenue $742M (+26% YoY) on DARZALEX + Kesimpta — largest pure-play royalty disclosure of W19	Thu 7 May
PTC Therapeutics	Q1 Evrysdi royalty $46.8M (last full pre-RPRX-monetization quarter)	Thu 7 May

FDA

Event	Sponsor	Date
ADMA ASCENIV pediatric sBLA	ADMA Biologics; PI age 2+ (was 12+)	Mon 4 May
Krystal KB407 + KB111 platform tech	Krystal Biotech (PDUFA VII; third KRYS program in 7 mo)	Mon 4 May
Nanobiotix / J&J NANORAY-312 amendment accepted	Interim removed; final analysis pulled forward	Mon 4 May
Nuvation Bio IBTROZI sNDA accepted	Taletrectinib ROS1+ NSCLC; target action 4 Jan 2027	Wed 6 May
Rznomics RZ-001 RMAT (HCC)	Korean trans-splicing ribozyme; AACR 2026 ORR 38.5%	Fri 8 May
Bizengri (zenocutuzumab-zbco) full sBLA approval	Partner Therapeutics; first-ever drug for NRG1+ cholangiocarcinoma; 7th CNPV pilot	Fri 8 May

IP / contract events

Event	Counterparties	Date
Ligand termination of Viking TR-Beta license	Ligand → Viking; covers VK2809 (MASH/MASLD) + VK0214 (X-ALD); Viking disputes	Effective Mon 4 May
Capricor v. Nippon Shinyaku / NS Pharma	Rescission lawsuit on 2022 deramiocel US distribution; CAPR -13% AH; PDUFA 22 Aug 2026	Thu 7 May
Catalyst / SERB / Hetero Firdapse settlement	Hetero generic licence Jan 2035; FTC + DOJ filing; terminates NJ litigation	Thu 7 May

Deal value table

Deal	Type	Headline	Date
UCB / Candid Therapeutics	M&A	$2.0B + up to $200M	Sun 3 May
MacroGenics / Sagard ZYNYZ	Royalty (expansion)	$60M + up to $20M; cap 1.7x→2.0x; aggregate Sagard $130M	Fri 1 May (8-K); announced Mon 4 May
Phoenix Asia Holdings / ACEA Pharma	M&A (all-stock RTO)	$1.0B all-stock (100M PHOE sh @ $10.00) + $20M convertible note; ACEA at ~82% pro-forma; Hong Kong / US Cayman; close Q2 2026	Mon 4 May
Cue Biopharma / Ascendant Health Sciences (Ascendant-221)	Out-license (ex-Greater China)	$15M up + up to $676.5M + tiered HSD-to-low-double-digit royalties; dual-mechanism anti-IgE Ph2 (CSU + food allergy); concurrent $30M Cue PIPE	Mon 4 May (Initial Closing)
Gyre Therapeutics / Cullgen (close)	M&A close (all-stock)	~$300M all-stock; adds targeted protein degraders + degrader-antibody conjugates (DACs) to Gyre's fibrosis platform; advisers Moelis (Gyre special committee) / Gibson Dunn (Gyre) / Mintz (Cullgen)	Mon 4 May
Lunai Bioworks / Oncotelic (N2B platform IP)	IP / asset acquisition	$20M Lunai preferred equity to acquire IP from two counterparties; $12.5M Lunai Series B convertible preferred to Oncotelic for nose-to-brain N2B platform; Lunai gets field-limited worldwide rights in biodefence countermeasures + Alzheimer's	4–6 May
Lexicon / Hercules Capital senior-secured term loan	Debt (non-dilutive)	Up to $100M (3 tranches); $55M funded at close; prime + 3.10% / 9.85% floor; 18-mo IO; maturity May 4, 2030	Mon 4 May (close); 8-K Wed 6 May
Ligand termination of Viking TR-Beta license	IP / contract event	Termination of May 2014 Master License covering VK2809 (MASH) + VK0214 (X-ALD); Ligand seeks non-exclusive worldwide royalty-bearing license; Viking disputes	Effective Mon 4 May (notice 24 Apr)
BioCryst / Neopharmed Gentili (navenibart EU)	Regional out-license	$70M + up to $275M + 18–30% royalties	Mon 4 May
Mirum VISTAS Phase 2b (PSC)	Clinical readout	Volixibat 20 mg BID hits primary; NDA 2H 2026	Mon 4 May
Lineage / Roche-Genentech RG6501	Phase 1/2a follow-up	+9 letters BCVA at 36 mo (n=5 sub-cohort)	Mon 4 May
Falk / Renexxion naronapride MOVE-IT	Phase 2b readout	20 mg TID p=0.0046 vs placebo, n=328	Mon 4 May
ADMA ASCENIV™ pediatric sBLA	Regulatory	PI age 2+ (was 12+)	Mon 4 May
Krystal KB407 + KB111 platform tech	Regulatory (PDUFA VII)	Third KRYS program in 7 months	Mon 4 May
Takeda TAK-881-3001 PID	Phase 2/3 readout	Recombinant hyaluronidase fSCIg; not Halozyme	Mon 4 May
Spur Therapeutics FLT201 (Gaucher)	Phase 1 follow-up	Bone marrow burden 11→7; ex-Freeline post-Q3 2025 Syncona take-private; no royalty layer	Mon 4 May
Cytokinetics ACACIA-HCM (nHCM)	Clinical readout	Royalty Pharma counterparty; dual primary KCCQ-CSS + peak VO2 met	Tue 5 May
Viridian REVEAL-2 (chronic TED)	Phase 3 readout	Elegrobart 50% Q4W / 54% Q8W proptosis response vs 15% placebo; VRDN +33%; DRI synthetic royalty counterparty	Tue 5 May
J&J JNJ-4804 Phase 2b IBD	Clinical readout	IL-23 + TNF-α co-antibody; positive in CD + UC; RPRX $500M R&D co-funding asset	Tue 5 May
Avalo AVTX-009 Phase 2 HS	Clinical readout	Anti-IL-1β; 42.9% HiSCR75; AVTX +18%	Tue 5 May
Madrigal / Arrowhead (ARO-PNPLA3)	Out-license (worldwide)	$25M up + up to $975M + tiered HSD-to-mid-teens royalties; RNAi MASH	Tue 5 May
Royalty Pharma / Revolution Medicines (2nd tranche)	Synthetic royalty (tranched)	$250M funded Mon 4 May under June 2025 $2B framework; 4.55% / 2.50% / 1.00% tiered on $0–2B / $2–4B / $4–8B daraxonrasib + zoldonrasib net sales; $750M capacity remaining	Mon 4 May (funded); Wed 6 May (10-Q disclosure)
Abivax (royalty certificate repurchase)	Reverse royalty	$90M total ($45M cash + $45M ADS at $111.57); cancels Sept 2022 royalty certificates ahead of obefazimod launch	Tue 5 May (announced); closing on/about Thu 7 May
Cellectar Biosciences (CLRB)	Structured financing	Up to $140M: ~$35M upfront + ~$105M milestone-based warrants; Nantahala-led; iopofosine I-131 WM	Tue 5 May
Merck / Terns Pharmaceuticals (close)	M&A close	$53.00/sh all-cash; ~$6.7B; TERN-701 BCR::ABL1 inhibitor	Tue 5 May
AIM ImmunoTech Ampligen Ph2 OC (UPMC)	Clinical readout	50% ORR; 21% CR; 79% CBR; mOS 32.5 mo; durable >70 mo	Tue 5 May (released Thu 7)
BioPharma Credit / Alphatec prepayment	Royalty/credit realization	$37.1M ($35M principal + $2.1M premium); 14.91% gross IRR / 11.93% net IRR	Tue–Wed 5–6 May
Avalo Therapeutics public follow-on	Capital markets	$375M at $17.75; post-AVTX-009 Ph2 HS readout	Tue 5 May
Citius Oncology / Avenue Venture Opportunities II	Debt + warrants	Up to $36.5M ($25M senior secured term loan + ~$11.5M warrant exercise); LYMPHIR launch	Tue 5 May
Nanobiotix / J&J NANORAY-312 (JNJ-1900 / NBTXR3)	Regulatory	FDA accepts Ph3 protocol amendment removing interim; final analysis pulled forward; HNSCC	Mon 4 May
Bayer / Perfuse Therapeutics	M&A	$300M up + up to $2.15B = up to $2.45B; PER-001 endothelin receptor antagonist Ph2	Wed 6 May
GSK / SiranBio (SA030)	Out-license (ex-Greater China)	$55M up + up to $1.0B + tiered royalties; ALK7 siRNA Ph1	Wed 6 May
Halozyme / Oruka (Hypercon™ / ORKA-001)	Drug-delivery license (global exclusive)	Upfront + milestones + mid-single-digit royalties to Halozyme; IL-23p19 in psoriasis + 1 option target	Wed 6 May
BeOne / Huahui Health (HH160 / BON-110)	Option to license (worldwide)	Trispecific PD-1 × VEGF-A × CTLA-4; terms not disclosed; BeOne Q1 release	Wed 6 May
MannKind / United Therapeutics (ralinepag DPI expansion)	License expansion	$5M up + up to $35M + 10% royalty; pulmonary hypertension + fibrotic lung disease	Wed 6 May
Mirum / Incyte (zilurgisertib worldwide)	Out-license (worldwide)	$16M up + milestones + tiered mid-to-high-single-digit royalties; ALK2 inhibitor in FOP; PDUFA 26 Sep 2026	Wed 6 May
Royalty Pharma Q1 2026 print	Earnings	PR $925M (+10%); RR $887M (+13%); cap deploy $528M actual / $1.25B announced (J&J $500M RIDS + Teva $500M RIDS + Zymeworks $250M royalty); FY guide raised	Wed 6 May
Travere Therapeutics convertible senior notes due 2032	Capital markets	$475M (upsized from $400M; +$60M opt); 0.50% / ~45% premium off $44.76 ref; Filspari = Ligand's largest current royalty driver	Wed 6 May
Viridian Therapeutics concurrent offerings	Capital markets	$350M aggregate: $225M 1.75% convert due 2032 + $125M equity (7.35M sh @ $17.00); ~$334.7M net; repays Hercules; post-REVEAL-2	Wed 6 May
Orchestra BioMed / Ligand RIPA final tranche	Royalty financing	$15M (final/2nd tranche; cash received 1 May); completes Ligand $35M total commitment under Aug 2025 Revenue Participation Right Purchase & Sale Agreement (AVIM Therapy + Virtue SAB)	Mon 6 May (announced)
Nuvation Bio (NUVB) IBTROZI sNDA acceptance	Regulatory	FDA accepts sNDA for taletrectinib in advanced ROS1+ NSCLC (updated DOR); target action Jan 4, 2027; updated TRUST-I/II data	Wed 6 May
Medicus Pharma SKNJCT-003 Phase 2 (nodular BCC)	Clinical readout	D-MNA / SkinJect doxorubicin microneedle array; 55% CR @ 200µg cohort, Day 57; positive dose-response; final CSR Q2 2026	Wed 6 May
Angelini Pharma / Catalyst Pharmaceuticals	M&A	$31.50/sh all-cash; ~$4.1B equity value; Firdapse/Fycompa/Agamree; Italian PE-backed (Blackstone funds + BNP Paribas global coordinator)	Thu 7 May
Roche / PathAI	M&A	$750M up + up to $300M = $1.05B; AI digital pathology + AISight IMS + CDx; close H2 2026	Thu 7 May
Halozyme / GSK (ENHANZE® oncology + ADCs)	Drug-delivery license (global)	Upfront + milestones + royalties on net sales to Halozyme; first ENHANZE deal to include ADC targets; first clinical trial 2026	Thu 7 May
BMS / Lonza (SYNtecan™ ADC linker-payload)	License (single target, exclusive)	Upfront + milestones + royalties to Lonza; ADC against undisclosed target	Thu 7 May
Entrada ELEVATE-44-201 Cohort 1 (DMD)	Phase 1/2 readout	Positive Cohort 1 data; Duchenne	Thu 7 May
Anagram Therapeutics / Blackstone Life Sciences	Structured (hybrid equity + royalty)	$250M structured investment; ANG003 oral non-porcine ERT for exocrine pancreatic insufficiency (CF); one of BXLS's largest single 2026 biotech investments	Thu 7 May
BridgeBio Pharma (BBIO) ATM + buyback authorization	Capital markets	$500M ATM capacity + concurrent $500M repurchase authorized; 8-K Thu 7 May	Thu 7 May
Capricor v. Nippon Shinyaku / NS Pharma	IP / contract event	Capricor (CAPR) files in NJ Superior Court seeking rescission of 2022 deramiocel US distribution agreement (originally $30M up + up to $705M); CAPR -13% AH; PDUFA Aug 22, 2026	Thu 7 May
Catalyst / SERB / Hetero (Firdapse patent settlement)	IP / settlement licence	Hetero receives licence to market generic Firdapse beginning January 2035; settlement to be submitted to FTC + DOJ; terminates pending New Jersey litigation; intersects with concurrent Angelini/Catalyst $4.1B M&A	Thu 7 May
Genmab Q1 2026 royalty disclosure	Earnings	Royalty revenue $742M (+26% YoY) on DARZALEX (J&J) + Kesimpta (Novartis); DARZALEX net sales $3.964B (+22%); largest pure-play royalty-income disclosure of W19	Thu 7 May
PTC Therapeutics Q1 2026	Earnings	Evrysdi (risdiplam) royalty revenue $46.8M (vs $36.4M Q1 2025); last full pre-RPRX-monetization quarter (Dec 2025 sale: $240M up + $60M milestones); 2026 product revenue guide raised to $750M–$850M	Thu 7 May
Incyte TRuE-AD4 Phase 3b 24-week long-term data	Clinical readout (Opzelura)	Positive: among Wk 8 EASI50 responders, 84.3% achieve EASI75 / 70.6% IGA-Treatment Success at Wk 24; supports EU Type-II MAA variation	Thu 7 May (EADV Symposium)
Cytokinetics $700M upsized follow-on (close)	Capital markets	9.86M sh × $71.00 = ~$700M gross; ACACIA-HCM-driven raise; Royalty Pharma direct counterparty (aficamten)	Fri 8 May
Odyssey Therapeutics IPO (priced Thu, debut Fri)	Capital markets	$304M gross ($279M IPO 15.5M sh @ $18 + $25M TPG PIPE); ODTX; OD-001 RIPK2 (UC)	Thu 7 / Fri 8 May
Mobia Medical IPO debut	Capital markets	$150M IPO @ $15.00 priced Thu eve; Nasdaq debut Fri; commercial-stage neuro-recovery device (ex-MicroTransponder)	Fri 8 May
Rznomics RZ-001 (HCC)	Regulatory (RMAT)	FDA RMAT designation; trans-splicing ribozyme platform; Korean origin; AACR 2026 ORR 38.5% confirmed (atezo+bev combo)	Fri 8 May
Raynovent ZSP1601 Ph2b (MASH)	Clinical readout	China-origin pan-PDE inhibitor; 64.9% response rate; Guangdong Raynovent Biotech	Fri 8 May
Kelun-Biotech / MSD (sac-TMT 1L NSCLC)	Regulatory milestone	NMPA sNDA accepted; PD-L1 TPS ≥1% NSCLC; 5th indication on out-licensed asset under priority review	Fri 8 May
Bizengri (zenocutuzumab-zbco) — Partner Therapeutics	FDA approval	Full sBLA approval — first-ever drug for NRG1+ cholangiocarcinoma under 7th National Priority Voucher (CNPV) pilot; voucher granted Wed May 6 enabling 1–2 mo review; eNRGy 36.8% ORR / DOR 2.8–12.9 mo; prior Breakthrough (Oct 2025) + Orphan (Feb 2026)	Fri 8 May

Capital markets (Mon 4 May)

Issuer	Type	Size	Notes
Aura Biosciences	Public + PFW	$260.3M	$6.00/sh + 3.8M PFW; ~$205M to bel-sar; Matrix $39M secondary
Cabaletta Bio	Registered direct	$150M	$2.90/sh; Bain LS, Adage, Cormorant, Lilly; runway mid-2027
Ocugen	Convert. notes 2034 (144A)	$115M (+$15M opt)	Terms TBD
CNS Pharmaceuticals	PIPE	$22.5M	$2.30/sh + PFW; ADAR1, Ikarian, Stonepine, Nazare
Hemab Therapeutics	IPO close	$346.7M	$18/sh; Goldman / Jefferies / Evercore
Seaport Therapeutics	IPO close	$254.9M	$18/sh; PureTech retains ~16.7M sh
Odyssey Therapeutics	IPO terms	~$238.3M target	$16–$18 range; ~$810M cap top of range
Indivior	Accelerated SBB	$175M	Barclays counterparty; $100M remaining

UCB / Candid Therapeutics (Sun 3–Mon 4 May)

$2.0B upfront + up to $200M milestones = up to $2.2B aggregate. All-cash; antitrust-conditioned close late Q2 / early Q3 2026.

Acquirer: UCB SA (Euronext Brussels: UCB)
Target: Candid Therapeutics, San Diego (private; founded Sept 2024 by Ken Song MD post-RayzeBio/BMS sale)
UCB legal counsel: Covington & Burling LLP
Effect: Definitively terminates Candid's announced March 2026 reverse merger with Rallybio ($505M concurrent financing)
UCB 2026 guidance: unchanged

Pipeline acquired

Asset	Modality	Stage
Cizutamig (lead)	BCMA × CD3	Late Phase 1; >100 patients dosed; >10 autoimmune indications (RA, MG, ILD); Phase 2 in MG and ILD planned
CND261	CD20 × CD3	Phase 1 dose-escalation completed in oncology; first H1 2026 autoimmune readouts
CND319	CD19 × CD20 × CD3 trispecific	Preclinical
Fourth	BCMA × CD19 × CD3 trispecific	Preclinical

Autoimmune-TCE pocket comparables

Transaction	Date	Headline	Lead asset
UCB / Antengene	Q1 2026	Up to $1.1B	ATG-201 (CD19×CD3)
Gilead / Ouro	Mar 2026	$1.7B + milestones	gamgertamig (BCMA×CD3)
Cullinan / Genrix	2025	Up to $712M	velinotamig + CD19×CD3 add-on
UCB / Candid (W19)	3–4 May 2026	Up to $2.2B	cizutamig + CND261 + 2 trispecifics

Read-through

Six-month thematic pocket: ~$5.7B disclosed value; combined upfronts approach $5.0B
Autoimmune TCEs structurally on par with ADCs as 2025–2026 dealmaking centre of gravity
Candid's upstream (EpimAb / Genor, China-origin) royalty terms not in W19 public domain — flow to UCB on close

Phoenix Asia Holdings / ACEA Pharma RTO (Mon 4 May)

$1.0B all-stock acquisition + $20M convertible promissory note. Phoenix Asia Holdings Limited (Nasdaq: PHOE; HK-domiciled Cayman company) entered a definitive Stock Purchase Agreement to acquire 100% of ACEA Pharma Inc. from Scilex Holding's (SCLX) indirect subsidiary ACEA Therapeutics, Inc.

Consideration: 100M newly-issued PHOE common shares at $10.00 reference = $1.0B headline equity value
Pro-forma ownership: ACEA Therapeutics ends at ~82% of pro-forma PHOE
Concurrent financing: separate $20M convertible promissory note issued to PHOE's controlling stockholder
Renaming: PHOE to be renamed ACEA Pharma post-close
Asset base: clinical-stage oncology + autoimmune + COVID-19 portfolio (specific lead asset disclosure to follow definitive proxy)
Closing: Q2 2026 expected, subject to HSR antitrust + Nasdaq stockholder approval
Cross-border structure: HK domicile / US Cayman / Nasdaq listing — characteristic of post-2024 China-origin biotech RTO template
SCLX implication: Scilex disposes of ACEA subsidiary into a public-listed shell, retaining indirect equity exposure via continuing ownership

Read-through

Largest disclosed all-stock RTO of a private clinical-stage biotech in 1H 2026; sits structurally adjacent to the Asia-origin reverse-takeover deal flow (Hutchmed pre-2021, BeiGene 2018)
Implied $10.00/sh PHOE reference is materially above the company's actual recent trading levels — the headline $1.0B is best read as a notional valuation peg rather than a market-tested clearing value; substantive close-conditional financing will determine actual capitalization
Concurrent $20M convertible promissory note to controlling stockholder is the operative liquidity bridge; characteristic of "reverse-merger-with-bridge" structures where the acquirer shell needs working capital through close
Read-through to Scilex (SCLX): partial monetization of the legacy ACEA Therapeutics portfolio without a cash-out; SCLX retains indirect upside via continuing equity stake in pro-forma PHOE/ACEA Pharma
Cross-border (HK domicile + US listing) Cayman shell + Asia-origin assets template likely to recur in 2026 given continued tightness of US biotech IPO window for sub-$100M-revenue companies

Gyre Therapeutics / Cullgen Acquisition Close (Mon 4 May)

Approximately $300M all-stock acquisition closed. Gyre Therapeutics (NASDAQ: GYRE) completed its previously-signed acquisition of Cullgen Inc., adding targeted protein degraders + degrader-antibody conjugates (DACs) to Gyre's fibrosis-anchored platform. Gyre subsequently disclosed the transaction value as ~$300M all-stock.

Transaction summary

Term	Detail
Acquirer	Gyre Therapeutics, Inc. (NASDAQ: GYRE; fibrosis-focused commercial-stage US/China)
Target	Cullgen Inc. (US/China; targeted protein degradation platform)
Closing	Monday 4 May 2026
Consideration	~$300M all-stock (per subsequent Gyre disclosure)
Strategic add	Targeted protein degraders + degrader-antibody conjugates (DACs)
Cross-border profile	US-listed acquirer + US/China target (both with significant China R&D operations)
Special-committee adviser	Moelis & Company
Gyre legal counsel	Gibson Dunn
Cullgen legal counsel	Mintz

Platform implications

Gyre's existing platform centred on hydronidone (anti-fibrotic; idiopathic pulmonary fibrosis; in-licensed via Continent Pharmaceuticals) plus pirfenidone capsules/franchise in China; Cullgen adds an entirely new modality — protein degradation
Cullgen's GT-153 (CDK2/4/6) and broader degrader pipeline expand Gyre into oncology + immunology adjacent to its core fibrosis franchise
DAC platform optionality is the operative 2026 deal-architecture theme: Cullgen's degrader-antibody conjugates parallel the broader 2026 ADC + DAC platform-licensing supercycle (Halozyme/GSK ENHANZE-ADC, BMS/Lonza SYNtecan, Tubulis/Gilead, Tubulis/BMS)

Cullgen upstream royalty obligation transferring to Gyre

The Gyre / Cullgen combination inherits Cullgen's pre-existing Astellas Pharma research collaboration and exclusive option agreement (June 2023; uSMITE™ targeted protein degradation platform):

Term	Detail
Counterparty (now Gyre)	Astellas Pharma Inc. (TYO: 4503)
Original signing	June 14, 2023
Upfront paid by Astellas	$35M (received by Cullgen pre-acquisition)
Lead-program option exercise	$85M (contingent on Astellas exercising license option for breast cancer / solid tumor cell-cycle protein degrader)
Aggregate deal value	Up to $1.9B (across all programs + milestones if all options exercised)
Royalty back to Gyre/Cullgen	Royalty payments on commercial sales (rate not publicly disclosed)
Lead asset	Cell-cycle protein degrader for breast cancer / solid tumors
Co-promotion option	Cullgen / Gyre retains right to co-promote partnered products in the US for the lead program (50/50 cost / profit / loss share)
Status	Astellas option not yet exercised as of W19; license decision pending clinical-development progress

Read-through

Astellas upstream relationship is the operative platform-economics layer that transfers to Gyre on close — Gyre now sits in line for the $85M option-exercise payment + downstream royalties + up to $1.9B aggregate if Astellas advances the uSMITE programs
Gyre's existing pirfenidone-class fibrosis royalty stack (Continent Pharmaceuticals upstream on hydronidone) now combines with the Astellas-Cullgen upstream and downstream royalty optionality on the uSMITE platform
All-stock structure preserves Gyre cash for clinical development and US commercial scale-up of pirfenidone-related franchise; characteristic of small-cap bolt-on M&A in 2026 weak biotech-financing environment
Cross-border (US/China-affiliated) M&A continues to be active despite geopolitical/regulatory friction; Gyre/Cullgen sits alongside Phoenix Asia/ACEA (W19), Hutchmed/Bristol Myers, and BeiGene-origin activity
For royalty-finance audience: targeted protein degraders + DACs as an emerging asset class for synthetic-royalty origination once Phase 2 / pivotal data emerge; Cullgen's GT-153 (CDK-degrader) potentially analogous to Verastem's Servier-licensed avutometinib/defactinib structure; the Astellas $1.9B uSMITE platform deal becomes a Gyre-controlled royalty-monetization candidate post any Astellas exercise event

MacroGenics / Sagard ZYNYZ Expansion (Mon 4 May)

$60M upfront + up to $20M 2026 sales-based milestone, expanding the original Jun 2025 Sagard agreement.

Combined economics

Term	Original Jun 2025	Expansion May 2026	Combined
Upfront	$70M	$60M	$130M base
Contingent	—	Up to $20M	Up to $20M
Total potential	$70M	Up to $80M	Up to $150M
Cap mechanic	2.0x ($140M)	Time-tiered	1.7x by Sept 30, 2032 (~$221–255M) OR 2.0x thereafter ($260–300M)
Royalty reversion	At 2.0x	Reverts to MGNX at cap	—

Sagard 2026 portfolio: dual operating mode

Position	Capital	Cap structure	Asset
Sagard / AnaptysBio Jemperli	$300M	Capped non-recourse $600–675M	GSK Jemperli; tiered 8/12/20/25%; 2025 sales >$300M Q3
Sagard / MacroGenics ZYNYZ (combined)	$130–150M	1.7x by Sept 2032 OR 2.0x thereafter	Incyte commercialization; Q1 2025 sales $3M (annualized ~$12M)

ZYNYZ context

PD-1 inhibitor; Incyte worldwide ex-Asia commercializer (Oct 2017 license)
Approvals: Merkel cell carcinoma (2023), SCAC (2024/2025); NSCLC combos in progress
Q1 2025 net sales $3M — ~$12M annualized

Read-through

Cap unreachable under current commercial profile — Sagard underwriting peak-sales trajectory under indication expansion
Time-tiered MOIC gives MGNX/Incyte residual upside if expansion succeeds, protects Sagard if it doesn't
$20M milestone-as-call-option architecture — operative Sagard sub-$200M template
MGNX cash runway extended into H1 2027
Second 2026 W-series Sagard transaction on the same asset within twelve months

BioCryst / Neopharmed Gentili Navenibart Europe (Mon 4 May)

$70M upfront + up to $275M milestones + tiered 18–30% royalties on European net sales = up to $345M before royalties.

Navenibart royalty genealogy

Territory	Date	Terms
Japan / Kaken Pharmaceutical	Aug 2025 (assumed Jan 2026)	$16M up + up to $16M + up to 30% tiered royalties + partial Phase 3 cost reimbursement
Europe / Neopharmed Gentili (Irish affiliate)	4 May 2026 (W19)	$70M up + up to $275M + 18–30% tiered royalties

Why 18–30% sits at top of 2026 European licensing

Pre-2025 European HAE rare-disease licenses historically priced at 8–15% top-tier — this is materially higher
BioCryst retains all US commercial rights and full pipeline optionality → 18–30% compensates for forgone EU launch economics
Neopharmed Gentili already operates the EU commercial infrastructure originally built by BioCryst for ORLADEYO → low incremental commercialization cost
HAE: concentrated, high-price-per-patient rare disease → 30% digestible at single-product net sales

Navenibart cost basis to BioCryst

Originated at Astria Therapeutics; BioCryst-owned post Jan 23, 2026 close
Per-share consideration: $8.55 cash + 0.59 BCRX shares = ~$13.00/share equity, ~$700M EV
Cash portion financed via cash on hand + ~$396.6M (net) drawn from $550M Blackstone facility
$70M Neopharmed Gentili upfront recovers ~10% of original cash portion in eight months

ORLADEYO upstream stack: zero-royalty tier now active

ORLADEYO global net sales crossed $550M in Q1 2026 (per BioCryst Mar 2026 investor materials).

Layer	Counterparty	Terms
US net sales	BioCryst (retained)	Direct revenue
Tiered royalty	OMERS Capital Markets	≥7.5% to $350M / 6.0% on $350–550M / 0% above $550M; 1.425x or 1.550x cap based on 2023 sales
Acquired royalty interest	Royalty Pharma (RPI)	$200M upfront paid Nov 2021 (with BCX9930 Factor D); rate not publicly itemized
EU pass-through	Neopharmed Gentili	Pays proportionate EU royalties at aggregate global rate

BioCryst capital position

Combined non-dilutive Neopharmed-Gentili-derived European cash: $320M in eight months (Oct 2025 ORLADEYO EU sale $250M + May 2026 navenibart $70M)
Phase 3 ALPHA-ORBIT and ORBIT-EXPANSE topline early 2027; US filing end of 2027

Read-through

30% top-tier band now established as the navenibart partnered-territory ceiling globally — first by Astria (Japan/Kaken), now by BioCryst (Europe/Neopharmed Gentili). Persistence across two independent licensors → market reference point, not one-off
Second-highest disclosed top-tier band in 2026 dealmaking after Protagonist / Takeda rusfertide US opt-out (29%, W18)
BioCryst US ORLADEYO net pre-tax cash flow now structurally elevated vs the 2021–2024 royalty-encumbered base case
BioCryst approaching a structurally simpler revenue / royalty profile than at any point since the November 2021 RPI + OMERS combined $350M financing

Mirum VISTAS Phase 2b PSC (Mon 4 May)

Volixibat met primary endpoint in primary sclerosing cholangitis. Potential first commercial therapy for cholestatic pruritus in PSC (no approved therapies).

Headline data

Metric	Volixibat 20 mg BID (n=54)	Placebo (n=57)	Δ	p
ItchRO LS-mean change	2.72	1.08	1.64 (placebo-adjusted)	<0.0001
≥2-pt itch responder rate	55.6%	26.3%	29.3 pp	0.0019
Serum bile acids change	-33.7	2.1	-35.8	0.0324
Time to response	<2 weeks	—	—	—

Trial: n=158 total (n=111 primary cohort moderate-severe itch; n=47 secondary mild itch)
Safety: diarrhea 40.3% vs 8.6%; more discontinuations on volixibat for AEs

Catalysts

Pre-NDA meeting: summer 2026
NDA submission (PSC): 2H 2026
Full data: EASL late-breaking oral, 30 May 2026, 2:15 p.m. CEST
VANTAGE Phase 2b PBC topline: Q1 2027 (delayed from H2 2026)

Volixibat upstream royalty stack

Counterparty	Role	Terms
Sanofi-Aventis Deutschland	Originator IP	Exclusive worldwide license to Mirum (assigned via Shire License Agreement Nov 2018); manufacturing + sublicensable rights
Pfizer	Originator (Pfizer Agreement)	Assigned via Shire License Agreement; expires country-by-country with Mirum royalty obligations
Lumena → Shire	IBAT platform; Shire acquired Lumena Jun 2014 (~$260M upfront)	IP integrated into Shire post-2014
Shire (now Takeda)	Direct licensor to Mirum (Nov 2018)	Up to $30M clinical/regulatory milestones for first volixibat indication ($2M paid Jan 2021) + tiered royalties on net sales (rate ranges not public)

Read-through

May 4 endpoint hit positions next milestone trigger at 2H 2026 NDA submission
VANTAGE PBC primary endpoint already hit in 2024 → volixibat is now a two-indication asset with both Phase 2b cohorts positive
First commercial launch establishes the rate-and-volume base for both upstream (Takeda) and downstream royalty cash flows
Same structural class as W18 Pfizer / Antecip Bioventures II / Axsome AUVELITY — Sanofi/Pfizer/Shire-castoff royalty layer becoming commercially activated
Takeda historically active monetizer of Shire-acquired royalty receivables (cf. Shire pre-deal HAE asset divestiture pattern) → receivable suitable for 2027/2028 monetization
At low-to-mid-single-digit royalty on PSC + PBC peak sales (consensus $500M+ each as first-in-disease therapies) → $50–150M tail-end peak, suitable for synthetic-royalty or capped-multiple monetization

Cytokinetics ACACIA-HCM Aficamten (Tue 5 May)

Phase 3 pivotal in non-obstructive HCM met both dual primary endpoints (KCCQ-CSS + peak VO2) and all key secondary endpoints. Royalty Pharma direct counterparty; CYTK +16.71% on the day. Single most material W19 RPRX-portfolio catalyst, now activated.

Headline read

Trial: Phase 3 ACACIA-HCM, n=420 nHCM patients (versus n=282 in oHCM SEQUOIA-HCM)
Both primary endpoints (KCCQ-CSS quality-of-life and peak VO2 exercise capacity) statistically significant
All key secondary endpoints met
nHCM is the larger of the two HCM subpopulations (~2x prevalence vs oHCM)
Aficamten approved as MYQORZO™ in oHCM Q4 2025; nHCM sBLA now expected late 2026/early 2027

RPRX three-transaction Cytokinetics position

Transaction	Date	Structure
Original RPR Purchase	7 Jan 2022	$150M total ($50M close + $50M oHCM Ph3 init + $50M nHCM Ph3 init); royalty 4.5% to $1B / 3.5% above; +$300M long-term capital tranche (1.9x)
Omecamtiv mecarbil restructure	Dec 2022	Adjusted following omecamtiv mecarbil regulatory pathway re-eval
Expanded Strategic Funding	22 May 2024	Up to $575M aggregate: $50M signing + up to $175M draw within 12 mo of oHCM approval (10yr, 1.9x); $100M for omecamtiv mecarbil Ph3 ($100M fixed + 2% incremental royalty on positive readout); $50M Cytokinetics secondary stock. Restructured aficamten royalty: 4.5% on first $5B / 1% above

Read-through

At 4.5% on first $5B: peak-mid-band annual royalty cash flow to RPRX up to $225M, with 1% above-$5B providing tail
Position embeds substantial near-term and structural optionality from omecamtiv mecarbil (HFrEF) component + $50M equity stake
Positive nHCM readout now confirmed: expands aficamten label beyond previously-approved oHCM → trajectory accelerates toward $5B mid-band threshold
15-year-plus duration RPRX position; one of the larger and longer-duration single-asset synthetic-royalty positions in the 2025–2026 portfolio set
RPRX explicitly cited the nHCM readout in Q1 2026 print Wed May 6 as a driver of guidance raise to $3.325–3.450B Portfolio Receipts FY2026

Lineage / Roche-Genentech RG6501 (Mon 4 May)

36-month Phase 1/2a follow-up data on OpRegen (allogeneic RPE cell therapy for GA secondary to dry AMD), presented at the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026.

Headline data

Population	n	Mean BCVA change at 36 mo
Cohort 4 extensive-bleb-coverage subgroup	5	+9.0 ETDRS letters (vs +7.4 at 24 mo)
Cohort 4 (less advanced GA)	10	+6.2 letters (vs +5.5 at 24 mo)

Single-administration cell therapy; subretinal delivery
OCT: partial restoration of outer retinal structure, RPE-layer re-appearance, photoreceptor recovery features
Improvement persisting from 12-month primary endpoint through 36 months

RG6501 royalty stack

Counterparty	Role	Terms
Roche / Genentech	Worldwide commercial licensee (20 Dec 2021 exclusive license)	$50M upfront paid + $5M development milestone paid + up to $615M remaining milestones + tiered double-digit royalties; royalties subject to IP-existence and competing-product offsets
Hadasit (Hadassah Medical Center tech transfer)	Upstream IP	Disclosed contribution; sub-license terms not public
Israeli Innovation Authority (IIA)	Government grant funding	Disclosed contribution
Lead manufacturing patent	US 11,746,324 (RPE large-scale production)	Expires 28 Jul 2036; exclusively licensed to Lineage

Read-through

Same therapeutic-area pocket as Apellis SYFOVRE® and Astellas/Iveric IZERVAY (both anti-C3 / anti-C5 complement inhibitors approved in GA), but structurally differentiated as a one-administration cell therapy with potential for visual function improvement rather than progression-slowing only
One of the cleaner sub-mid-cap upstream royalty positions on a Phase 2a-stage cell therapy in the publicly-disclosed 2025–2026 set
Hadasit/IIA layer reflects the Israeli academic-and-government IP funnel (cf. Iveric Bio / Wills Eye / NIH avacincaptad pegol; Pluri Inc placental cell platform)
At tiered double-digit royalty on Roche-commercialized net sales → 2027/2028 royalty-monetization candidate subject to Phase 2a GAlette study readouts and Roche pivotal-path commitment

Falk / Renexxion Naronapride MOVE-IT (Mon 4 May)

Positive Phase 2b MOVE-IT (NCT05621811) topline in gastroparesis. Late-breaking oral at DDW 2026 Chicago, 2–5 May. Trial enrolled n=328 adults with moderate-to-severe idiopathic or diabetic gastroparesis; double-blind 12-week TID dosing at 10/20/40 mg vs placebo.

Primary endpoint (ANMS GCSI-DD Core Symptom Score)

Arm	n	LS-mean change	Δ vs placebo	p (Dunnett-Hsu)
10 mg TID	83	-1.244	-0.138	0.3112
20 mg TID	80	-1.512	-0.405	0.0046
40 mg TID	80	-1.452	-0.346	0.0156
Placebo	85	-1.106	—	—

Secondary signals

Composite score (excl. vomiting): 20 mg p=0.0024, 40 mg p=0.0117
Responder rate: ~15–20% incremental over placebo at 20 mg or 40 mg; no added benefit of 40 mg over 20 mg
GEBT (gastric emptying breath test): 20 mg -21.95 min vs -10.96 min placebo
No new safety signals (cardiac, neuropsychiatric, prolactin); minimal systemic absorption confirmed across cumulative >1,200-subject database (9 Ph1 + 5 Ph2)

Naronapride asset background

ATI-7505, a soft analog of cisapride engineered at ARYx Therapeutics using the RetroMetabolic ("ARM") platform technology
Designed to retain 5-HT4 agonism / D2 antagonism while avoiding the cardiac CYP450 metabolism issues that drove the global Propulsid (cisapride, Janssen) and Zelnorm (tegaserod, Novartis) withdrawals
Locally active in gut lumen with minimal systemic absorption; main metabolite ATI-7500 is inactive and rapidly eliminated

Naronapride licensing chain

Stage	Date	Counterparties	Terms
Discovery	2002–2006	ARYx Therapeutics (Fremont CA)	Engineered via RetroMetabolic platform as cisapride soft-analog
First out-license	2006	ARYx ↔ Procter & Gamble	P&G ran 4 Phase 2s (n=982); rights returned Jul 2008 post-cisapride/tegaserod regulatory pause
ARYx wind-down → Renexxion	post-2010	ARYx ↔ Renexxion LLC (later Renexxion Inc., California)	Founded by ARYx co-founders Milner (CEO) and Druzgala (CSO) with Atheneos Capital backing; Armetheon's Ken Kengatharan as chair
Greater China sublicense	17 Jul 2018	Renexxion ↔ Sinovant Sciences (Roivant China subsidiary)	Exclusive PRC + HK + Macau + Taiwan; license fee + commercial milestones + tiered royalties; initial indication IBS-C
Europe + ROW sublicense	5 Oct 2021	Renexxion Ireland ↔ Dr. Falk Pharma (Freiburg)	Upfront + dev funding + clinical/regulatory/sales milestones + tiered double-digit royalties; territory: Greater Europe (incl. UK), Russia, Central Asia, certain Australasian countries
Indication expansion	7 Feb 2024	Same structure	Falk elects PPI-nrsGERD as second indication; undisclosed milestones
US re-entry	13 Aug 2024	FDA IND clearance; first US patient dosed in MOVE-IT	Renexxion retains US, Japan, China-ex-Sinovant rights

Read-through

Second-tier-counterparty multi-territory royalty stack — not Royalty-Pharma-scale, but coherent layered structure
Renexxion sits as upstream licensor on two parallel sublicensees (Falk EU/ROW + Sinovant Greater China); US/Japan retained directly
Dr. Falk Pharma is privately held and a recognized European GI specialist (autoimmune hepatitis, eosinophilic esophagitis, ulcerative colitis, primary biliary cholangitis) → naronapride aligns with their established commercial channel
Renexxion privately held → not currently a public-market royalty-monetization candidate
Future Renexxion liquidity event (IPO, M&A, or selective royalty-stream monetization) would crystallize dual-territory royalty receivable + retained US/Japan economics
With Phase 2b primary endpoint now met across two indications (gastroparesis + the 2024 PPI-nrsGERD extension) and Phase 3 readiness in CIC, naronapride moves to the late-stage rare-class GI prokinetic category
Late-stage rare-class GI prokinetic territory: metoclopramide is only FDA-approved gastroparesis treatment with black-box warning
GLP-1-induced delayed gastric emptying overlap opens substantial second-line adjunct opportunity
20 mg likely registration dose (no added benefit at 40 mg)
Registration studies targeted later 2026

Takeda TAK-881-3001 PID (Mon 4 May)

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIg)
Positive pivotal Phase 2/3 topline in primary immunodeficiency disease
Supports BLA filing 2026/2027
Takeda's own recombinant hyaluronidase technology — not Halozyme rHuPH20 ENHANZE
No third-party royalty layer at the program level
Competitive read-through to Halozyme ENHANZE-partnered Ig portfolio

Spur Therapeutics FLT201 (Mon 4 May)

AAV gene therapy in Gaucher disease Type 1 Phase 1 additional follow-up data
Bone marrow burden score improved from 11 to 7
Spur Therapeutics is the rebranded entity post-Q3 2025 Syncona-led take-private of Freeline Therapeutics
Privately held; no public royalty layer

ADMA Biologics ASCENIV™ Pediatric sBLA (Mon 4 May)

Item	Detail
Approval date	4 May 2026
Asset	ASCENIV™ (immune globulin intravenous, human – slra 10% liquid)
New scope	PI in pediatric patients age 2+ (was 12+)
Originator	ADMA Biologics; FDA-licensed plasma fractionation, Boca Raton FL
IP	Proprietary plasma donor screening + patented microneutralization assay; multiple US/intl patents
Royalty layer	None at program level
Implications	Specialty IVIG franchise extension; broader pediatric access

Krystal KB407 + KB111 Platform-Tech Designations (Mon 4 May)

Program	Indication	Designation
KB801	Neurotrophic keratitis	HSV-1 platform-tech (14 Oct 2025)
KB407	Cystic fibrosis	Platform-tech (4 May 2026)
KB111	Hailey-Hailey disease	Platform-tech (4 May 2026)

Three KRYS programs under PDUFA VII pathway in seven months
First applications of platform-tech designation to a topical / non-systemic gene therapy delivery platform
Proprietary HSV-1 vector; no upstream royalty layer
Read-through to W18 LEO / Replay synHSV ($50M upfront, DEB Phase 1/2; Pittsburgh Glorioso lab upstream license)

Viridian REVEAL-2 Elegrobart Phase 3 (Tue 5 May)

Positive Phase 3 in chronic thyroid eye disease. VRDN +33.36% on the day. Sets up dual filings (active + chronic TED) and direct competitive frame against Amgen/Horizon Tepezza (teprotumumab) franchise. DRI Healthcare $300M synthetic royalty position activated.

Headline data

Arm	Dosing	≥2 mm proptosis responder rate (Week 24)
Elegrobart Q4W	Every 4 weeks	50%
Elegrobart Q8W	Every 8 weeks	54%
Placebo	—	15%

Both Q4W and Q8W arms highly statistically significant vs placebo (p<0.0001)
Elegrobart: anti-IGF-1R monoclonal antibody (next-generation Tepezza-class)
Trial: REVEAL-2 in chronic TED (>16 months disease duration)
BLA planned for Q1 2027 (chronic TED)
Veligrotug (active TED) PDUFA: 30 June 2026, near-term commercial inflection

DRI Healthcare synthetic royalty position (activated)

Term	Detail
Announced	20 Oct 2025
Counterparty	DRI Healthcare Acquisitions LP (DRI Healthcare Trust; TSX: DHT.UN / DHT.U)
Asset coverage	Veligrotug (VRDN-001) and elegrobart (VRDN-003), US net sales
Total commitment	Up to $300M
Upfront paid	$55M
Near-term milestones	Up to $115M tied to positive VRDN-003 (elegrobart) topline + US regulatory progress
Additional milestones	Up to $130M residual structure
Structure	Non-recourse synthetic royalty on US net sales

Third synthetic royalty + second pre-approval deal in DRI's portfolio history
DRI's existing veligrotug exposure was already a near-term active-TED commercial play (PDUFA 30 Jun 2026); the elegrobart Phase 3 success converts the second leg of the position from contingent to high-confidence
Near-term $115M milestone tranche now significantly de-risked
Position now spans both active TED + chronic TED on a single non-recourse synthetic royalty structure

Tepezza competitive context

Tepezza is Amgen-acquired (post-Horizon $28B Oct 2023 close), originated at River Vision/Cambridge Antibody, in-licensed by Roche, divested to Horizon
2025 Tepezza net sales $1.9B (Amgen FY2025 disclosure)
Halozyme ENHANZE-partnered for SC formulation (Tepezza SC pivotal trial active)
Amgen does not disclose Tepezza royalty stack publicly post-Horizon integration
Viridian elegrobart on next-generation IgG1κ engineered for higher-affinity IGF-1R binding + lower IGF-1 cross-reactivity → thesis: superior efficacy / safety vs Tepezza in head-to-head data

Elegrobart upstream royalty stack

Counterparty	Role	Terms
ImmunoGenesis (formerly Paragon Therapeutics)	Originator IP	Disclosed Viridian-Paragon May 2020 collaboration; single-digit to low-double-digit tiered royalties on net sales; option/license model (Viridian exercised exclusive option)
Veligrotug origination	Same Viridian-Paragon platform	Same royalty layer
DRI Healthcare (downstream synthetic)	Synthetic royalty on US net sales of both assets	Up to $300M total; $55M paid Oct 2025; up to $245M further milestones

Read-through

Confirms IGF-1R class as two-asset late-stage commercial candidate for Viridian (veligrotug active TED Q3 2026 PDUFA + elegrobart chronic TED 2027 BLA)
DRI Healthcare position now a credible 2027/2028 portfolio cash-flow generator at scale; one of DRI's larger and more strategically positioned single-platform exposures
ImmunoGenesis/Paragon emerges as clean upstream royalty layer on a near-launch ophthalmology-class asset: a 2027/2028 monetization candidate post both regulatory events
Tepezza-class TAM (TED + chronic TED) materially expands with chronic-disease label; chronic TED population ~3x active TED
Sub-mid-cap upstream royalty discovery model (Paragon Therapeutics / ImmunoGenesis): same structural template as Aiolos/GSK depemokimab and Versant Ventures Spruce Biosciences
W19 establishes elegrobart + veligrotug as the clearest current example of a multi-counterparty royalty stack on a Tepezza-class asset (Paragon upstream + DRI downstream synthetic + Viridian commercial)

J&J JNJ-4804 Phase 2b IBD (Tue 5 May)

Positive Phase 2b in both Crohn's disease and ulcerative colitis for J&J's IL-23 + TNF-α co-antibody. RPRX direct counterparty via $500M R&D co-funding agreement (announced 30 Mar 2026).

Headline read

Asset: JNJ-4804, IL-23 (p19) + TNF-α dual-mechanism antibody combination
Phase 2b topline positive in both CD and UC
Positions JNJ-4804 as a successor / portfolio extension to Tremfya (guselkumab; IL-23 monotherapy)
Phase 3 program initiation expected H2 2026

RPRX JNJ-4804 R&D co-funding structure

Term	Detail
Announced	30 Mar 2026
Capital	$500M over 2026–2027
Structure	R&D co-funding (not royalty purchase)
Royalty / return mechanism	Tiered single-digit royalty on JNJ-4804 net sales (terms not fully disclosed)

JNJ-4804 component royalty stack

JNJ-4804 is a fixed-dose subcutaneous combination of guselkumab (Tremfya, anti-IL-23) + golimumab (Simponi, anti-TNF-α) — both J&J in-house biologics. The combination inherits the upstream royalty stacks of both components.

Component	Origin	Upstream royalty layer
Guselkumab (Tremfya)	J&J / Janssen + MorphoSys HuCAL platform	MorphoSys low-single-digit tiered royalty (originally up to ~5%; partially monetized — Royalty Pharma acquired MorphoSys's Tremfya royalty interest via the December 2021 $325M up + up to $250M milestones transaction); RPRX-Tremfya position is therefore the operative upstream royalty layer
Golimumab (Simponi)	J&J / Centocor (in-house)	No third-party royalty stack
JNJ-4804 (combination)	J&J fixed-dose combo	Inherits MorphoSys/RPRX layer on guselkumab portion only

Read-through

Validates RPRX R&D co-funding modality (Teva TEV-'408 vitiligo Jan 2026 $500M; J&J JNJ-4804 Mar 2026 $500M = $1.0B aggregate H1 2026)
Positive Ph2b readout de-risks RPRX position 5 weeks after deal announcement
RPRX double-take on JNJ-4804: RPRX simultaneously holds (a) the upstream MorphoSys-origin royalty on guselkumab/Tremfya (acquired Dec 2021) and (b) the new R&D co-funding tiered royalty on JNJ-4804 itself (Mar 2026); the combination antibody therefore generates two parallel royalty receivables to RPRX if commercialized
Tremfya is already an RPRX top-3 royalty driver (cited by RPRX in Q1 2026 print as Royalty Receipts growth driver); JNJ-4804 represents the next-generation extension of the same revenue stream
Tremfya + JNJ-4804 layered positioning gives RPRX two-decade RPRX-J&J immunology runway
Modality replication probable: expect 2–3 additional R&D co-funding announcements in H2 2026

Avalo AVTX-009 Phase 2 HS (Tue 5 May)

Positive Phase 2 topline in hidradenitis suppurativa. AVTX +18% on the day. Asset name now finalized as abdakibart.

Headline data

Metric	AVTX-009 (abdakibart)
HiSCR75 response	42.9%
Mechanism	Anti-IL-1β monoclonal antibody
Phase	Phase 2
Indication	Moderate-to-severe HS

AVTX-009 (abdakibart) royalty stack

Layer	Counterparty	Economics
Origin	Eli Lilly (originally discovered/developed)	Out-licensed to AlmataBio April 2023
Intermediate licensor	AlmataBio, Inc. (private; founded April 2023 specifically to license AVTX-009)	Acquired by Avalo March 2024 (subsidiary)
Avalo / AlmataBio acquisition	Avalo paid AlmataBio shareholders $22.5M upfront ($15M stock + $7.5M cash) + up to $20M in development milestones ($5M Ph2 patient dosed; $15M Ph3 patient dosed)	Phase 2 trigger paid; Phase 3 milestone restructured April 2026 to $7.375M total
Lilly royalty (upstream, in force)	Lilly receives 5% to 15% of Avalo / sublicensee annual net sales of AVTX-009 (per Avalo 10-K)	Country-by-country expiry; in force from first commercial sale

Read-through

HS competitive landscape: AbbVie Humira (TNF-α, off-patent), Novartis Cosentyx (IL-17A, approved HS Oct 2023), J&J Tremfya (IL-23, Ph3 readout pending)
IL-1β mechanism differentiated from approved IL-17/IL-23 axis; potential add-on or salvage positioning
Lilly 5-15% upstream royalty layer is materially significant: any future Avalo synthetic-royalty monetization or full asset sale must clear the Lilly stack before downstream financing economics
Sub-$200M market cap pre-W19 → post-readout $375M follow-on Tue 5 May enables Phase 3 self-financing (vs. forced out-license / take-private path); $375M raise materially de-risks the Lilly royalty obligation by reducing dilutive financing pressure
HS Tepezza-style asset class continues attracting late-stage royalty financing interest; abdakibart sits at the intersection of inflammation + IL-1β class as a 2027/2028 synthetic-royalty candidate post-Phase 3 readout

Madrigal / Arrowhead ARO-PNPLA3 Worldwide License (Tue 5 May)

$25M upfront + up to $975M dev/reg/commercial milestones + tiered royalties high-single-digits to mid-teens on commercial net sales = up to $1.0B before royalties. Arrowhead's third partnered cardiometabolic asset in 12 months (after Sanofi Aug 2025 and BMS earlier 2026); Madrigal's second siRNA license deal of 2026.

Transaction summary

Term	Detail
Licensor	Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Licensee	Madrigal Pharmaceuticals (NASDAQ: MDGL)
Territory	Exclusive worldwide
Upfront	$25M (paid at closing)
Contingent	Up to $975M dev/reg/sales milestones
Royalties	Tiered high-single-digits to mid-teens on net sales
Asset	ARO-PNPLA3 (formerly JNJ-75220795)
Platform	Arrowhead TRiM™ targeted RNAi platform

Acquired asset

ARO-PNPLA3: clinical-stage RNAi therapy designed to silence hepatocyte expression of PNPLA3
Indication: MASH in patients homozygous for PNPLA3 I148M variant (~30% of MASH patients with moderate-to-advanced fibrosis; especially prevalent in Hispanic populations)
Phase 1 data published in NEJM: 46% reduction in liver fat at 12 weeks after a single dose in homozygous I148M patients
Reductions onset by 6 weeks; sustained at least 24 weeks; well-tolerated safety profile
Second Phase 1 study (n=9, Japan) supportive
Originally developed under Arrowhead-J&J 2018 collaboration (part of $3.7B biobucks partnership); J&J returned rights in 2023 amid pipeline reprioritization

ARO-PNPLA3 royalty stack (post-deal)

Counterparty	Role	Terms
Madrigal Pharmaceuticals	Worldwide commercial licensee	Pays Arrowhead $25M up + up to $975M + tiered HSD-to-mid-teens royalties
Arrowhead Pharmaceuticals	Originator + royalty recipient	Receives milestones + royalties; retains TRiM™ platform broader optionality
Johnson & Johnson	Prior 2018-2023 collaborator	Rights returned to ARWR in 2023; no residual J&J royalty layer disclosed

Madrigal MASH combination strategy (2025–2026)

Deal	Date	Counterparty	Asset / class	Terms
Madrigal / CSPC	Jul 2025	CSPC Pharmaceutical	Preclinical oral GLP-1 agonist	$120M up + milestones
Madrigal / Pfizer	Early 2026	Pfizer	DGAT2 inhibitor	$50M up
Madrigal / Ribo Life Science	Feb 2026	Ribocure (Sweden subsidiary)	6 preclinical siRNA programs	Up to $4.4B (heavily backloaded)
Madrigal / Arrowhead (W19)	5 May 2026	Arrowhead	ARO-PNPLA3 RNAi	$25M up + up to $975M + HSD-mid-teens royalties

Arrowhead 2025-2026 strategic-partner cardiometabolic out-licensing pattern

Deal	Date	Counterparty	Asset	Terms
Arrowhead / Sarepta	Apr 2024	Sarepta	Multi-program muscle / CNS	Up to $11B+ across 7 programs
Arrowhead / Sanofi	Aug 2025	Sanofi	Plozasiran-class (China rights)	$140M up
Arrowhead / Madrigal (W19)	5 May 2026	Madrigal	ARO-PNPLA3 (worldwide)	$25M up + up to $975M + HSD-mid-teens royalties

Read-through

Disclosed royalty rate range (HSD to mid-teens) is a clean public pricing reference for clinical-stage RNAi licensing in metabolic disease; sits broadly in line with Sanofi-Arrowhead and the broader 2025-2026 RNAi partnership comparable set
Backloaded structure ($25M up vs $975M backloaded; 2.6% upfront ratio) reflects pre-NDA risk profile + J&J return-of-rights diligence overhang
Arrowhead emerges as one of the most active 2025-2026 strategic-partner royalty licensors in cardiometabolic / RNAi, with three disclosed partnered streams now generating royalty optionality
Madrigal's W19 deal sits within a broader pivot from single-asset (Rezdiffra) to MASH combination franchise: 4 BD deals in 12 months across THR-β + GLP-1 + DGAT2 + RNAi
Arrowhead Q1 2026 print (pre-W19) highlighted ALK7 obesity program (ARO-ALK7) as differentiated mechanism, same target class as W19 GSK / SiranBio SA030; competitive read-through is direct
ARO-PNPLA3 royalty receivable suitable for 2028/2029 synthetic-royalty-monetization candidacy post first Madrigal Phase 2 readout
Madrigal Q1 2026 earnings call Wed 6 May (post-deal) framed broader MASH BD strategy

Merck / Terns Pharmaceuticals Acquisition Close (Tue 5 May)

$53.00/share all-cash acquisition closed; tender offer expired 11:59 p.m. ET Mon 4 May with 86.36% (100.09M shares) tendered. Merger completed Tue 5 May; Terns delists from Nasdaq Global Select Market.

Transaction summary

Term	Detail
Announced	March 2026 (W11)
Closed	Tue 5 May 2026 (W19)
Consideration	$53.00/sh all-cash; ~$6.7B total
Tender offer result	86.36% tendered (100.09M sh)
Financing	Cash on hand + 364-day delayed-draw term loan facility
Status	Wholly-owned Merck subsidiary; Nasdaq delisting filed 5 May

Acquired pipeline

TERN-701: oral allosteric BCR::ABL1 tyrosine kinase inhibitor; Phase 1 chronic myeloid leukemia (CML); FDA Fast Track designation
TERN-601 GLP-1 receptor agonist (obesity; Phase 1 program preserved)
TERN-501 THR-β agonist (MASH; Phase 2)

Read-through

Merck post-Keytruda LOE strategy continues: $9.2B Cidara Therapeutics (CD388 long-acting flu, late 2025) + $6.7B Terns (TERN-701 CML) + Verona Pharma (Ohtuvayre COPD, ~$10B Mar 2025)
TERN-701 positions Merck against Novartis Scemblix (asciminib; allosteric BCR::ABL1, approved 2024) in CML salvage / second-line
No public royalty layer at TERN-701 program level: Terns originated programs internally
Adds another sub-$10B platform M&A datapoint to the 2026 cumulative tally; thematic continuity with Sun Pharma / Organon ($11.75B, W17) and the broader Q1 $15.6B biopharma M&A run-rate

Bayer / Perfuse Therapeutics Acquisition (Wed 6 May)

$300M upfront + up to $2.15B development, regulatory, and commercial milestones = up to $2.45B total. All-cash; Bayer's first pharma M&A since 2021 (multi-year drought ended). Strategic Eylea-LOE hedge.

Transaction summary

Term	Detail
Acquirer	Bayer AG (XTRA: BAYN)
Target	Perfuse Therapeutics, Inc. (South San Francisco; private)
Upfront	$300M cash
Contingent	Up to $2.15B in dev/reg/commercial milestones
Total	Up to $2.45B
Close	Subject to antitrust + Perfuse stockholder approval

Acquired asset

PER-001: small molecule endothelin receptor antagonist
Sustained-release intravitreal implant; ~6-month dosing interval
Phase 2 in glaucoma + diabetic retinopathy
Pre-clinical work in dry AMD + retinal vein occlusion
Mechanism: vascular-centric neuroprotection (non-VEGF, non-IOP)

Strategic rationale

Eylea (aflibercept; co-marketed with Regeneron, Bayer ex-US) faces biosimilar competition; first Bayer pharma acquisition since 2021 explicitly framed as Eylea-LOE pipeline replacement
PER-001 mechanism complements Bayer's existing VEGF anti-angiogenic franchise with disease-modifying neuroprotection thesis
Treatment burden fatigue: 6-month dosing addresses key real-world adherence gap in retinal therapy
Glaucoma: ~80M global patients; no approved disease-modifying therapy
Diabetic retinopathy: ~146M global patients

Read-through

Royalty layer at Perfuse program level not disclosed in transaction announcements; Perfuse Series A/B venture cap table includes typical institutional terms (no announced public royalty receivable)
Bayer M&A reactivation signal: additional $5–10B bolt-ons probable through 2026/2027 to backfill Eylea
Endothelin pathway reactivation precedent for synthetic-royalty financing should PER-001 advance to registration trials → 2028/2029 monetization candidate
Sits adjacent to W18 Lineage / Roche-Genentech RG6501 ophthalmology cluster; the dry retinal disease therapeutic-area pocket continues to consolidate at premium valuations

GSK / SiranBio SA030 ex-Greater China License (Wed 6 May)

$55M upfront + up to $1.0B development/regulatory/commercial milestones + tiered royalties on net sales outside Greater China = up to $1.055B before royalties. GSK's second China-origin siRNA deal in 10 weeks (Frontier Biotechnologies $40M + $963M, Feb 2026).

Transaction summary

Term	Detail
Licensor	Suzhou Siran Biotechnology Co., Ltd. (SiranBio); private
Licensee	GSK plc (LSE: GSK)
Territory	Worldwide ex- mainland China, Hong Kong, Macau, Taiwan
Upfront	$55M
Contingent	Up to $1.0B milestones
Royalties	Tiered (rate ranges not disclosed)

Acquired asset

SA030: long-acting siRNA oligonucleotide
Target: activin receptor-like kinase 7 (ALK7)
Phase 1 in cardiometabolic disease (lung, liver, kidney; vascular risk reduction)
ALK7 mechanism: TGF-β superfamily receptor; modulates adipose tissue function (proposed mechanism for selectively reducing visceral / abdominal fat while preserving lean mass)

GSK 2026 China-origin siRNA position

Deal	Date	Counterparty	Terms	Asset / target
GSK / Frontier Biotechnologies	Feb 2026 (W08)	Frontier Biotech	$40M + up to $963M	Two siRNA assets (immunology)
GSK / SiranBio	6 May 2026 (W19)	SiranBio	$55M + up to $1.0B + tiered royalties	SA030 (ALK7; cardiometabolic / obesity)

Read-through

GSK siRNA platform consolidation continues post-Arrowhead 2024 ($1.0B upfront + $11.5B in milestones for plozasiran/MASH siRNA portfolio); Arrowhead is therefore the structural anchor and Frontier + SiranBio are tactical ALK / immunology bolt-ons
ALK7 is a contested obesity mechanism: Arrowhead has its own ALK7 program (ARO-ALK7); Lilly preclinical activity disclosed; Pfizer pre-Metsera radar
Cross-China-origin siRNA licensing intensifying: GSK is a representative late-mover in China-origin siRNA platform plays, with broader trend includes Lilly/Insilico ($2.75B Mar 2026), AbbVie/RemeGen ($5.6B), AstraZeneca/CSPC obesity ($18.5B)
No upstream royalty layer disclosed at SA030 program level; Suzhou Siran venture-financed
SiranBio's $1.055B GSK economics imply Series B/C valuation re-rate; potential 2027/2028 IPO candidate on the HKEX 18A pre-revenue biotech track

Halozyme / Oruka Hypercon™ ORKA-001 License (Wed 6 May)

Upfront + milestones + mid-single-digit royalties on net sales of Hypercon-enabled products. Global exclusive collaboration and license agreement between Halozyme Hypercon, Inc. (Halozyme's wholly-owned subsidiary) and Oruka Therapeutics. Covers ORKA-001 plus an option for one additional target.

Transaction summary

Term	Detail
Licensor	Halozyme Hypercon, Inc. (Halozyme Therapeutics subsidiary; Nasdaq: HALO)
Licensee	Oruka Therapeutics (Nasdaq: ORKA)
Territory	Global exclusive
Upfront	Disclosed but unquantified
Contingent	Milestone payments (unquantified)
Royalties	Mid-single-digit on net sales of Hypercon-enabled products
Asset coverage	ORKA-001 (IL-23p19 mAb in psoriasis + related inflammatory diseases) + 1 option target
Technology	Hypercon™ microparticle hyperconcentration platform (in-licensed from Surf Bio Jan 2026)

Hypercon partner roster (2026 buildout)

Counterparty	Date	Asset / target
Janssen / J&J	pre-2026	undisclosed
Eli Lilly	pre-2026	undisclosed
argenx	pre-2026	undisclosed
Vertex Pharmaceuticals	7 Apr 2026	up to 3 drug targets; deal valued at $15M
Oruka Therapeutics (W19)	6 May 2026	ORKA-001 (IL-23p19) + 1 option target; mid-SD royalties

Read-through

Second 2026 Hypercon collaboration in 30 days (Vertex Apr 7 → Oruka May 6) validates Halozyme's drug-delivery royalty franchise diversification beyond the legacy ENHANZE® rHuPH20 portfolio; mid-single-digit royalty band is below the historical ENHANZE rate range, consistent with platform-license-on-platform-license stacking economics
Tepezza-class IGF-1R precedent reads through: Halozyme's ENHANZE-partnered Tepezza SC (Amgen / Horizon legacy) is the operative reference for SC-formulation royalty layer durability as a Tepezza generation deals through W19 (Viridian REVEAL-2)
Oruka cap-table now stacks Hypercon platform royalty + IL-23p19 commercial license royalty layers; combined royalty obligations should be modeled as a single Oruka-side commercial overhang
ORKA-001 IL-23p19 mechanism positions Oruka as a direct competitor to J&J Tremfya + AbbVie Skyrizi; Hypercon SC differentiation is the operative commercial moat

MannKind / United Therapeutics Ralinepag DPI Expansion (Wed 6 May)

$5M upfront + up to $35M development milestones + 10% royalty on net sales. Expansion of the existing dry-powder inhalation (DPI) collaboration to add fibrotic lung diseases (PH-ILD, IPF) alongside the original pulmonary hypertension indication.

Transaction summary

Term	Detail
Licensee	United Therapeutics (NASDAQ: UTHR)
Licensor	MannKind Corporation (NASDAQ: MNKD)
Asset	Ralinepag inhaled DPI (IP-receptor agonist; Technosphere® powder formulation)
Indication expansion	Pulmonary hypertension (existing) + fibrotic lung diseases (PH-ILD, IPF; new)
Upfront	$5M
Contingent	Up to $35M development/regulatory milestones
Royalty	10% on net sales

Read-through

Cleanly disclosed double-digit royalty rate on a pulmonology DPI sits at the high end of inhaled-drug-delivery royalty norms (5–8% historical for ENHANZE-class SC-conversion deals; 10% reflects Technosphere platform contribution + clinical-stage asset risk)
MannKind royalty stack continues to consolidate around UTHR (Tyvaso DPI $99M Q1 2026 royalty run-rate; ralinepag DPI as next-gen extension) → MannKind/UTHR royalty pair sits as a credible 2027/2028 synthetic-royalty-monetization candidate post-ralinepag commercial inflection
Ralinepag origin: Arena Pharmaceuticals (acquired by UTHR Jan 2022 for $800M cash); MannKind's DPI formulation work follows the Tyvaso DPI playbook
Read-through to RPRX upstream Tyvaso receivable (acquired via Liquidia / United Therapeutics 2018 royalty-on-Tyvaso): residual layer behavior under DPI label expansion is a tracking item

Cue Biopharma / Ascendant Health Sciences Ascendant-221 License (Mon 4 May Initial Closing)

$15M upfront + up to $676.5M in milestones + tiered HSD-to-low-double-digit royalties. License signed 30 April 2026 with Initial Closing on/about 4 May 2026 (W19 8-K disclosure). Exclusive global ex-Greater China license to Ascendant-221 (formerly UB-221), a Phase 2 dual-mechanism anti-IgE monoclonal antibody.

Headline economics

Component	Amount
Upfront	$15M (delivered via 551,724 pre-funded warrants under separate SPA)
Tech-transfer milestone	$5M
Data / know-how milestone	$6.5M
Development + regulatory milestones	Up to $205M
Commercial milestones	Balance to up to $676.5M aggregate
Royalties	Tiered high-single-digit to low-double-digit on net sales

Asset profile

Ascendant-221 (formerly UB-221): dual-mechanism anti-IgE mAb; binds free IgE + uniquely targets IgE on B cells via CD23 low-affinity receptor; Phase 2 in chronic spontaneous urticaria (CSU); food allergy in development
Origin: United BioPharma (UBP) — Taiwan-based late-clinical-stage biopharma (Hsinchu, Taiwan; subsidiaries in Shanghai + Yangzhou; liaison offices in US); originally developed by United Biomedical Inc. (Hauppauge NY) + UBI Asia (Hsinchu)
TFDA-approved Phase 2 CSU trial initiated May 2022; double-blind placebo-controlled; long-acting add-on therapy with two IV doses at 3-month interval
Differentiation from omalizumab (Xolair) + ligelizumab: UB-221 in free or IgE-complex form interacts with IgE:CD23 complex — feature not observed in any other anti-IgE mAb; targets IgE toward non-inflammatory CD23 pathway; Phase 1 demonstrated weeks-to-months IgE suppression after single dose

Ascendant-221 royalty stack (post-license)

Layer	Counterparty	Economics
Origin / upstream	United BioPharma (UBP), Taiwan + United Biomedical Inc., NY	UBP retains Greater China commercial rights; specific UBP-Cue upstream-license terms not in W19 public domain
Cue Biopharma intermediate license	UBP → Cue Biopharma (Cue holds ex-Greater China rights from UBP)	Out-licensed to Cue prior to W19 sublicensing
Ascendant Health Sciences sublicense (W19)	Cue → Ascendant Health Sciences	$15M up + up to $676.5M + tiered HSD-low-double-digit royalties to Cue
Cue net royalty position	Difference between Ascendant downstream royalty + UBP upstream royalty	Spread economics not public; characteristic of mid-cap intermediary licensing

Concurrent CUE financing

$30M PIPE at Cue Biopharma: pre-funded warrants + warrants at $11.00/unit
Newbridge Securities placement agent
Funds Ascendant-221 development support + Cue's broader pipeline

Read-through

Cross-border out-license structure (Taiwan-origin asset re-licensed by US biotech to ex-Greater China developer) is a notable inversion of the typical 2025-2026 China-out-licensing template; suggests a maturing two-way licensing market for pre-Phase 3 Asia-origin assets
Three-tier royalty stack (UBP upstream → Cue intermediate → Ascendant downstream) is operationally complex; characteristic of small-cap biotech intermediary licensing where the originator (UBP) lacks ex-Asia commercial scale and the developer (Ascendant) lacks Asia origination capacity
Royalty rate band (HSD-to-low-double-digit) sits below first-line anti-IgE comps (~10-15% market norm for omalizumab-class assets) reflecting Phase 2 development stage and ex-Greater China geographic carve-out
$15M upfront is modest relative to total deal value (2.2% of headline) — characteristic of milestone-loaded option-style structures where development risk transfers to the licensee
Concurrent $30M Cue PIPE supports the non-cash $15M upfront mechanic (pre-funded warrants) — the structure is functionally a license-financing combo
Adds Cue Biopharma to the W19 royalty-bearing licensor list alongside Mirum (zilurgisertib), MannKind (ralinepag), Halozyme (Oruka, GSK), and BMS-Lonza
CD23-pathway targeting differentiation from Xolair/ligelizumab is the operative commercial thesis; if Ascendant-221 demonstrates Xolair-superiority in pivotal CSU readouts, the asset becomes a credible 2027/2028 synthetic-royalty-monetization candidate at Ascendant level

Lunai Bioworks / Oncotelic — N2B Platform Asset Transfer (4–6 May)

$20M Lunai preferred equity issuance to acquire IP from two counterparties; $12.5M of that consideration directed to Oncotelic Therapeutics in Lunai Series B convertible preferred stock. Smaller-cap platform asset acquisition — included for completeness given platform-strategy implications and an unusual cross-counterparty preferred-equity-as-consideration structure.

Transaction summary

Term	Detail
Acquirer	Lunai Bioworks (private; US neuroscience platform)
Aggregate consideration	$20M preferred equity issuance (Lunai Series B convertible preferred)
Disclosed component	$12.5M to Oncotelic Therapeutics (OTLK) in Lunai Series B convertible preferred stock
Asset acquired (Oncotelic component)	N2B (nose-to-brain) platform — intranasal CNS delivery technology
Field grant	Worldwide rights to Lunai in biodefence countermeasures + Alzheimer's disease (field-limited)
Other counterparty	Not publicly named in surfaced disclosures
External advisers	None publicly identified

Read-through

Stock-for-stock consideration to a public company (Oncotelic, OTLK) rather than cash is the operative innovation; private acquirer + public seller cross-equity structure is uncommon and worth tracking as a 2026 reference comp
For Oncotelic: receives $12.5M of Lunai Series B convertible preferred (non-cash); creates contingent upside on Lunai's pipeline development outcome; preserves Oncotelic's residual rights outside the Alzheimer's + biodefence carve-outs
For Lunai: gains a CNS-delivery platform without cash outlay plus optionality on biodefence countermeasures (DARPA-/BARDA-relevant indications); positions Lunai as a multi-platform neurotherapeutics consolidator
Asset-transfer structure (preferred equity for IP) sits adjacent to the broader 2026 trend of non-cash bolt-on M&A for cash-constrained acquirers; comparable to Phoenix Asia / ACEA all-stock RTO (also W19) at much smaller scale

Mirum / Incyte Zilurgisertib Worldwide License (Wed 6 May)

$16M upfront + dev/reg/sales milestones + tiered mid-to-high-single-digit royalties on worldwide net sales. Mirum acquires exclusive worldwide rights to zilurgisertib (ALK2 inhibitor) for fibrodysplasia ossificans progressiva (FOP). PDUFA September 26, 2026 — near-commercial royalty-bearing asset.

Transaction summary

Term	Detail
Licensor	Incyte Corporation (NASDAQ: INCY)
Licensee	Mirum Pharmaceuticals (NASDAQ: MIRM)
Territory	Exclusive worldwide
Upfront	$16M
Contingent	Development + regulatory + sales milestones (aggregate not fully disclosed)
Royalties	Tiered mid-to-high-single-digit on worldwide net sales
Asset	Zilurgisertib (oral ALK2 / ACVR1 kinase inhibitor)
Stage	NDA accepted; PDUFA 26 Sep 2026
Indication	Fibrodysplasia ossificans progressiva (FOP); ultra-rare progressive heterotopic ossification

Strategic rationale

Mirum bolts on a second near-commercial rare-disease asset, complementing volixibat (W19 PSC Phase 2b primary-endpoint hit, NDA 2H 2026) and the existing LIVMARLI (maralixibat) franchise
Bolt-on operationalizes Mirum's rare-disease commercial infrastructure (US salesforce + medical affairs scaled for cholestatic rare disease) into adjacent ultra-rare bone disorder
Incyte rationale: deprioritizing non-core assets outside hem/onc + dermatology focus; recoups program development cost via upfront + milestone + royalty stack

Read-through

PDUFA 26 Sep 2026 makes this a Q3 2026 commercial-launch candidate — the most near-term royalty-bearing licensing deal of W19 and one of the cleanest 2026 Q4 royalty-monetization candidates if approval lands
Tiered mid-to-high-single-digit royalty sits in line with Incyte's typical out-license rate band (cf. Incyte/MorphoSys, Incyte/Syros historical comparables)
Mirum royalty stack now extends across three commercial / near-commercial assets (LIVMARLI + volixibat + zilurgisertib); upstream-royalty-payer profile crystallizing as near-term synthetic-royalty monetization candidate for Mirum itself (cf. existing HCRx / DRI / RPRX precedents on Mirum's own LIVMARLI)
FOP commercial pocket: Ipsen Sohonos (palovarotene) is incumbent (approved Aug 2023 US; ~$200M annualized 2025); zilurgisertib differentiated mechanism + oral kinase profile vs RAR-γ agonist

Royalty Pharma Q1 2026 Print (Wed 6 May, pre-market)

Q1 2026 print headlines: Portfolio Receipts $925M (+10%), Royalty Receipts $887M (+13%), Capital Deployment $528M, FY2026 guidance raised. Reported pre-market Wed 6 May. Most material royalty-vehicle data point of the W17–W19 cycle.

Q1 2026 financials

Metric	Q1 2026	Q1 2025	YoY
Portfolio Receipts	$925M	$839M	+10%
Royalty Receipts	$887M	$788M	+13%
Net cash from operations	$718M	$596M	+20%
Capital Deployment	$528M	—	—
Operating + professional costs	$36M	—	—

Q1 2026 capital deployment ($528M actual; $1.25B announced)

Transaction	Date	Capital
Teva TEV-'408 R&D co-funding	Jan 2026	Up to $500M ($75M Ph2b + $425M optional Ph3); vitiligo
Zymeworks Ziihera royalty	Mar 2026	$250M (HER2+ biliary tract / gastric; Jazz / BeOne commercializers)
J&J JNJ-4804 R&D co-funding	Mar 2026	$500M over 2026–2027; IL-23 + TNF-α co-antibody (W19 Ph2b positive readout)

FY2026 guidance raise

Metric	Previous	Updated	Δ
Portfolio Receipts	$3,275–3,425M	$3,325–3,450M	+$25–50M low / +$25M high
Royalty Receipts growth	+3% to +8%	+4% to +8%	+1pp at floor
FY interest paid	—	$350–360M	—

Q2 2026 receipts seasonality

Q2 2026 Portfolio Receipts guided to $740–760M (vs Q1 $925M)
Reflects seasonal upward-tiering royalties resetting to lower rate Q1 → flowing through to RPRX Q2 with one-quarter lag
Mechanical, not deterioration

Read-through

R&D co-funding modality validated ($1.0B aggregate H1 2026: Teva $500M + J&J $500M); Legorreta explicitly framed this as a "novel funding modality"
Q1 capital deployment $528M represents strong start vs FY2026 implied $1.5–2.0B run-rate for new-deal capital
Aficamten (MYQORZO) nHCM positive readout Tue 5 May explicitly cited in earnings call as a portfolio catalyst; RPRX raised guidance partly on aficamten label expansion confidence
Promacta LOE + Tysabri biosimilar headwinds absorbed into raised guidance, i.e. new-deal accretion is offsetting legacy run-off faster than prior outlook
Returns on invested capital ~14%, returns on invested equity ~20%; reaffirms RPRX as the structural reference point for capped-multiple synthetic royalty pricing
Share repurchase $50M + 7% dividend increase; total Q1 capital return $186M

Royalty Pharma / Revolution Medicines Second Tranche (Mon 4 May funded; disclosed Wed 6 May 10-Q)

$250M second tranche funded under the June 2025 $2.0B synthetic-royalty agreement, triggered by positive RASolute 302 daraxonrasib PDAC data (April 2026). With this tranche, RPRX is now entitled to tiered royalties of 4.55% on daraxonrasib net sales $0–$2B, 2.50% on $2–$4B, and 1.00% on $4–$8B (covers zoldonrasib in overlapping indications). $750M of additional capacity remains; if fully drawn, top-tier royalty steps up to 7.80% / 4.55% / 2.40%.

Transaction summary

Term	Detail
Royalty buyer	Royalty Pharma plc (RPRX)
Asset originator	Revolution Medicines (RVMD)
Asset coverage	Daraxonrasib (RAS(ON) inhibitor) + zoldonrasib in overlapping indications
Trigger	Positive RASolute 302 Phase 3 PDAC data (April 2026)
Tranche size	$250M (second of three tranches under June 2025 framework)
Royalty structure	Tiered: 4.55% on net sales $0–$2B / 2.50% on $2–$4B / 1.00% on $4–$8B
Remaining capacity	$750M; if fully drawn → top-tier rates step up to 7.80% / 4.55% / 2.40%
Disclosure	Surfaced via RPRX 10-Q filed Wed 6 May; funding date Mon 4 May

Why this matters

Single most material genuinely net-new royalty-fund deployment of W19 — surfaced via 10-Q rather than press release; cleanest disclosed tiered-royalty structure in the W19 set
Tranched synthetic royalty modality continues to crystallize as RPRX's preferred 2026 deployment template alongside RIDS — June 2025 RVMD framework is now the operative reference deal for $2B+ synthetic-royalty commitments structured as data-trigger-tranched draws
Tiered-step-down structure (4.55% → 2.50% → 1.00%) reflects RPRX's explicit revenue-tier modeling: caps total royalty cash exposure at higher net-sales levels, preserves IRR floor at lower volumes
Read-through to RPRX FY26 deployment: $528M Q1 actual + $250M RVMD second tranche + announced pipeline = ~$1.5B already committed YTD against $2.0–$2.5B implied annual run-rate
Daraxonrasib RAS(ON) franchise sits as the highest-conviction near-term oncology royalty asset across the public royalty-fund universe by 2030 NPV; pivotal PDAC + first-line NSCLC readouts 2026/2027

Angelini Pharma / Catalyst Pharmaceuticals (Thu 7 May)

$31.50/share all-cash; total equity value ~$4.1B (~€3.5B). 21% premium to Catalyst's unaffected close (April 22, last trading day before market signs of pending transaction); 28% premium to 30-day VWAP. Boards of both companies unanimously approved. Closing expected Q3 2026.

Transaction summary

Item	Detail
Buyer	Angelini Pharma S.p.A. (Italian privately held; Angelini Industries Group; €1.6B FY2024 group turnover; operates 21 countries)
Target	Catalyst Pharmaceuticals (CPRX), Coral Gables FL; rare/difficult-to-treat neurological diseases
Consideration	$31.50/sh cash; ~$4.1B equity value
Premia	21% to unaffected April 22 close; 28% to 30-day VWAP
Financing	Blackstone funds + select international partners; BNP Paribas as global coordinator and underwriter
Approvals	Both boards unanimous; HSR + customary regulatory; Q3 2026 close
Strategic frame	Angelini's first US presence; positioning as "global player in neurological rare diseases"

Acquired commercial portfolio + upstream royalty stack

This is the royalty-finance angle: Catalyst's three commercial assets each carry distinct upstream royalty obligations now transferring to Angelini.

Asset	Indication	2025 status	Upstream royalty obligation
Firdapse (amifampridine phosphate)	LEMS adult + ped 6+	Lead asset; ~$0.5B+ run-rate	7% to BioMarin on first $100M NA net sales / 10% above (7-year tail from first NA commercial sale, 2018); plus separate 7% to original third-party licensor
Fycompa (perampanel CIII)	Epilepsy (focal + PGTC)	US rights acquired Jan 2023 from Eisai for $160M cash	Contingent milestone payment + royalty to Eisai (terms undisclosed in deal-close PR); ~45% physician-call-point overlap with Firdapse
Agamree (vamorolone)	DMD age 2+	In-licensed from Santhera April 2023 (NA + MX + UK)	Tiered royalties to Santhera (Santhera reports them as royalty income); Catalyst earns sublicense royalties from Kye Pharmaceuticals on Canadian rights (July 2024 sublicense)

Net: Angelini inherits a stacked royalty obligation structure across all three assets, which is unusual at this acquisition size. Public-disclosure economics imply the Firdapse upstream stack alone exceeds the 10% combined royalty rate (BioMarin 7-10% + third-party 7%) on incremental NA sales above the $100M tier within the active royalty term.

Strategic rationale

Angelini is best known in Europe for fluvoxamine, dexketoprofen, and the rare-disease focal/segmental epilepsy franchise built around cenobamate (Ontozry, Bial-licensed). Catalyst broadens the portfolio with three US-listed commercial-stage neurological rare-disease products and operationalizes US commercial infrastructure that Angelini has historically lacked. The 3% headline-print premium reported in the initial Reuters wire (vs prior-day close) reflects Catalyst's 30%+ YTD share-price run; the unaffected-baseline premium of 21–28% (pre-leak) is the more economically meaningful figure.

The Blackstone funds + BNP Paribas financing structure is consistent with a senior-acquisition-debt + sponsor-equity package backing a privately held strategic, not a take-private LBO. This sits adjacent to (but does not overlap with) the Blackstone Life Sciences synthetic-royalty franchise.

Read-through

Second-largest M&A event in W19 behind Merck/Terns ($6.7B close) and ahead of Bayer/Perfuse ($2.45B); the all-cash structure at $4.1B at a 28% VWAP premium continues the 2026 pattern of strategic acquirers paying full price for de-risked commercial-stage rare-disease assets
For royalty-finance audiences: stacked upstream royalty obligations on acquired commercial assets are the relevant due-diligence point, not the buyer's cap-table. BioMarin remains a residual royalty receiver on Firdapse for the next ~10 months of the 7-year tail (depending on the precise 2018 first-commercial-sale date); Eisai retains contingent-payment rights on Fycompa US sales; Santhera continues to earn royalties on Agamree throughout
PE-backed private strategic emerges as a buyer category: Angelini's transaction profile (privately held strategic + Blackstone fund support + BNP Paribas global coordinator) is structurally distinct from both classic strategic M&A and pure financial sponsor LBO; it overlaps with the structures used by EQT-backed IFM Pharma and similar PE-strategic hybrids in 2025
Italian pharma cross-Atlantic activity reinforced: builds on Recordati (which has been actively acquiring rare-disease commercial assets) as a second Italian-house presence in the US neurological rare-disease space; suggests an emerging "Italian PE-strategic" clutch active in this segment
No royalty monetization signaled by Catalyst as part of the transaction (i.e. no Sagard/HCRx/RPRX-style structured-royalty solution attached); the upstream royalty obligations transfer with the assets in the standard course

Catalyst / SERB / Hetero — Firdapse patent settlement (Thu 7 May, concurrent)

Same day as the Angelini take-private announcement, Catalyst and licensor SERB Pharmaceuticals announced a Hatch-Waxman patent-litigation settlement with Hetero. Hetero receives a licence to market generic Firdapse beginning January 2035. The settlement will be submitted to the FTC and DOJ and terminates the pending New Jersey patent litigation.

Term	Detail
Patent owner	SERB Pharmaceuticals (France; specialty rare disease)
Sublicensor	Catalyst Pharmaceuticals (US Firdapse marketer; subject of W19 Angelini take-private)
Generic licensee	Hetero Drugs Limited (India; ANDA filer)
Generic launch licence	January 2035
Regulatory clearance	Submission to FTC + DOJ
Litigation status	Terminates pending District of New Jersey case

Read-through to Angelini transaction: the Firdapse generic-entry date of January 2035 is now contractually fixed for Hetero — operative input into Angelini's Catalyst valuation underwriting. From a Catalyst-shareholder perspective, the Firdapse exclusivity tail is materially clearer than before the settlement, even if the implied PV impact on the $31.50/sh take-private price is small (most of the Firdapse value is in the 2026–2032 window). For SERB's upstream royalty stack on Firdapse (BioMarin 7-10% historical layer that is rolling off, plus Catalyst's commercial royalty obligations to SERB), the settlement preserves the Firdapse cash-flow profile through the launch-of-generic threshold.

Roche / PathAI Acquisition (Thu 7 May)

$750M upfront cash + up to $300M in milestone-contingent earn-out = $1.05B total deal value. Definitive merger agreement; close H2 2026. Roche Diagnostics absorbs PathAI to scale AISight Image Management System globally and accelerate AI-powered companion diagnostics.

Transaction summary

Term	Detail
Acquirer	Roche Diagnostics (SIX: ROG; OTCQX: RHHBY)
Target	PathAI (Boston-based; private; AI digital pathology)
Upfront	$750M cash
Contingent	Up to $300M milestone earn-out
Total	Up to $1.05B
Close	H2 2026 (subject to customary conditions)
Strategic angle	AISight Image Management System + AI biomarker discovery + CDx algorithms
History	Roche–PathAI partnership since 2021; expanded 2024

Read-through

Largest disclosed AI-pathology M&A since J&J / Auris (2019) for medical-device AI; the $300M milestone earn-out is the operative royalty-like upside layer — terms not disclosed but historically Roche structures these as commercialization-milestone events
Roche Diagnostics' royalty-bearing CDx partnerships with biopharma developers run through this division; PathAI integration creates an AI-augmented CDx co-development royalty platform structurally analogous to Halozyme's drug-delivery franchise but on the diagnostics side
Latham & Watkins advised PathAI; transaction valuation disclosed via Roche IR materials
European pharma cluster context: Thu 7 May produced three European-pharma-led deal announcements on a single day — Angelini / Catalyst ($4.1B Italian US-market entry), Roche / PathAI ($1.05B Swiss diagnostics expansion), Halozyme / GSK ENHANZE-ADC (UK partnership). Strongest single-day European pharma BD print of 2026 to date

Halozyme / GSK ENHANZE® Oncology + ADC License (Thu 7 May)

Upfront + milestone payments + royalties on net sales. Global collaboration and license agreement granting GSK access to ENHANZE® drug delivery technology for subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs) plus an option for additional future targets. First ENHANZE collaboration to include ADC targets. First clinical trial projected to initiate in 2026.

Transaction summary

Term	Detail
Licensor	Halozyme Therapeutics (Nasdaq: HALO)
Licensee	GSK plc (LSE: GSK; NYSE: GSK)
Territory	Global
Upfront	Disclosed but unquantified
Contingent	Milestone payments (unquantified)
Royalties	Royalties on net sales of products incorporating ENHANZE (rate band not disclosed)
Asset coverage	Multiple oncology targets, including ADCs; option for additional future targets
First clinical trial	2026

Why this is structurally significant

First ENHANZE deal to include ADC targets: extends Halozyme's drug-delivery royalty franchise from the historical mAb / fusion-protein population (Darzalex, Phesgo, Vyvgart, Tecvayli, Hyqvia) into the single fastest-growing oncology modality of 2025–2026
ADC class context: BMS / SystImmune iza-bren ($8B+ collaboration, Feb 2026 Ph3 readout); BMS / Lonza SYNtecan™ single-target license same-day W19 (see next section); BMS / Tubulis 2023 ($22.75M up + $1B+ + tiered royalties); broader ADC dealmaking running at 2–3x 2024 pace
Halozyme-side royalty model: ENHANZE products historically deliver mid-to-high-single-digit tiered royalties on partnered net sales (cf. Darzalex SC contribution to Halozyme FY2025 royalty receipts), with this deal expanding the optionable target universe materially
GSK-side rationale: GSK ADC pipeline includes Blenrep (belantamab mafodotin; relaunched 2026 post-DREAMM-7/8 readouts) + several preclinical/Phase 1 programs; SC formulation differentiation against Daiichi Sankyo / AstraZeneca Enhertu is an explicit Halozyme call-out

Halozyme drug-delivery royalty franchise (W19 cumulative state)

Platform	2026 active partner count	W19 deals
ENHANZE® rHuPH20	10+ commercialized products across >100 markets	+ GSK (Thu 7 May; oncology + ADCs)
Hypercon™ microparticle	Janssen, Lilly, argenx, Vertex, Oruka	+ Oruka (Wed 6 May; IL-23p19); two W19 collaborations

Read-through

Two Halozyme royalty-bearing collaborations on consecutive days: Wed Oruka (Hypercon, mid-SD royalty) → Thu GSK (ENHANZE oncology + ADC, royalty rate not disclosed) → cleanest single-week royalty franchise expansion in 2026 to date
HALO Q1 2026 earnings 11 May 2026 will frame deal economics + royalty-receipts cadence; H.C. Wainwright PT $95 Buy / TD Cowen PT $96 Buy reflect strong royalty-growth thesis
Extends Halozyme's positioning as the dominant public-market drug-delivery royalty originator alongside Alnylam (RNAi) and Arrowhead (RNAi); 2026 platform partnership cadence implies a two-decade recurring royalty receivable suitable for synthetic-royalty monetization on a per-product basis
Halozyme insider context: Darren Snellgrove (ex-J&J IR head) appointed CFO effective 8 Jun 2026 (announced Apr 30); active CFO transition during peak BD cadence

BMS / Lonza SYNtecan™ ADC Single-Target License (Thu 7 May)

Upfront + milestone payments + royalty payments on net sales. Exclusive single-target licensing agreement; BMS gains exclusive access to Lonza's SYNtecan™ linker-payload platform to advance an ADC against an undisclosed target. BMS responsible for research, development, manufacturing and commercialization.

Transaction summary

Term	Detail
Licensor	Lonza Group AG (SIX: LONN), via affiliated company
Licensee	Bristol Myers Squibb (NYSE: BMY)
Structure	Exclusive single-target license
Territory	Global (implied)
Upfront	Disclosed but unquantified
Contingent	Milestone payments (unquantified)
Royalties	Royalty payments on net sales of resulting products
Asset	ADC against undisclosed target using SYNtecan™ linker-payload platform
BMS responsibilities	R&D + manufacturing + commercialization

Why this matters for royalty-finance audiences

CDMO-originated platform royalty stream is an emerging structural innovation: Lonza historically a manufacturing services revenue model; SYNtecan™ licensing pivots Lonza into the same recurring-royalty origination model occupied by Halozyme (drug delivery), Arrowhead (RNAi), and Alnylam (RNAi)
Single-target structure caps Lonza's economic exposure but provides reference comparable for future SYNtecan™ licensing rounds (tracker for 2026/2027 Lonza royalty deal cadence)
BMS ADC dealmaking pattern (post-SystImmune iza-bren licensing 2023, Tubulis P5+Tubutecan platform 2023, Orum ORM-6151 2023): third disclosed BMS ADC platform license in 36 months — BMS positioning as a multi-platform ADC late-mover behind AstraZeneca/Daiichi Sankyo Enhertu franchise

Read-through

ADC linker-payload platform licensing (Tubulis P5/Tubutecan + Lonza SYNtecan™ + Cellectar/Mariana radioconjugates) crystallizing as a new royalty-bearing technology layer within the broader ADC stack
Lonza-side: first major royalty-bearing license disclosed under the SYNtecan™ brand; expect 2–3 additional partnerships in next 18 months as BMS validation reads through
Lonza royalty receivable on a successful BMS ADC product would be a post-2030 monetization candidate (commercial inflection 2030+ on Phase 1 start)
Read-through to W19 Halozyme/GSK ENHANZE + ADC deal: ADC-class subcutaneous formulation + linker-payload licensing now both active royalty-bearing modalities same-day Thursday W19, marking 7 May 2026 as a notable ADC platform-royalty dealmaking print

AIM ImmunoTech Ampligen Phase 2 Ovarian (UPMC; Thu 7 May)

UPMC final primary endpoint report on Ampligen® (rintatolimod) + pembrolizumab + cisplatin in recurrent ovarian cancer. 50% ORR (12/24 evaluable patients; 5 CR + 7 PR), 21% complete response rate, 79% clinical benefit rate, median OS 32.5 months, durable responses >70 months, no Grade 4–5 toxicities.

Mechanism + structural context

Ampligen (rintatolimod): dsRNA TLR3 agonist immunomodulator; lead AIM ImmunoTech asset; IP protection extends into 2039
Trial sponsorship: financially supported by Merck grant (Keytruda combo); ClinicalTrials.gov NCT03734692; Robert P. Edwards, MD (UPMC) PI
Indication: platinum-sensitive recurrent ovarian cancer; intraperitoneal cisplatin + IV pembrolizumab + IP Ampligen; up to six 3-week cycles
Secondary endpoint data collection completes Jan 2027

Read-through

AIM Capital Equels framing: strategic partnership-readiness signal — AIM positions Ampligen as a checkpoint-inhibitor-augmenting agent with potential expansion into pancreatic cancer
Sub-$10M market cap microcap (NYSE American: AIM trading near $0.49); royalty-finance angle is licensee-development not direct synthetic-royalty origination
Ovarian cancer combo asset class context: clean sub-$1B partnership pocket adjacent to Merck's Keytruda lifecycle management; tracking item for 2026/2027 small-cap immuno-oncology BD pipeline

BioPharma Credit / Alphatec Senior-Secured Prepayment (Tue–Wed 5–6 May)

$37.1M realized on the Alphatec Holdings (ATEC) prepayment of its $200M senior secured loan. 14.91% gross IRR / 11.93% net IRR over the 18-month hold (originated 31 October 2024). Sole disclosed royalty / pharma-credit fund-side realization in the W19 window.

Transaction summary

Term	Detail
Lender	BioPharma Credit PLC (LSE: BPCR) — managed by Pharmakon Advisors, LP
Borrower	Alphatec Holdings, Inc. (NASDAQ: ATEC)
Original facility	$200M senior secured loan
Origination	31 October 2024
Prepayment	5 May 2026 (full principal + accrued interest + prepayment fees)
BPCR realization	$37.1M ($35M principal share + $2.1M prepayment fees / accrued interest); confirmed by RNS 6 May
Gross IRR	14.91%
Net IRR	11.93%
Hold period	~18 months

Why this matters

Cleanest disclosed senior-secured prepayment economics print of 2026 to date — the 14.91% gross IRR / 11.93% net IRR sits squarely within Pharmakon's targeted 8–9% net total return on NAV, with prepayment fees + accrued interest providing the upside vs base-case yield
Pharmakon Advisors (BPCR.L investment manager) has now committed $11B across 74 transactions (2009 inception; per current Pharmakon disclosure); recent 2026 deals include Erleada structured royalty (March 2026; sole purchaser), Zenas BioPharma $250M senior secured (March 2026), UroGen Pharma refinanced $250M senior secured (February 2026)
BPCR.L Q1 2026 earnings release will frame this realization; reinvestment of $37.1M proceeds is the implicit forward-deployment question for BPCR shareholders
Read-through to broader pharma-credit asset class: prepayment optionality as a structural alpha contributor in senior-secured pharma loans; Pharmakon's Alphatec realization is a textbook reference comp for 2026/2027 underwriting templates

Anagram Therapeutics / Blackstone Life Sciences Structured Investment (Thu 7 May)

$250M structured investment from Blackstone Life Sciences (BXLS). One of the largest single biotech investments in BXLS's 2026 deployment book. Hybrid ownership-plus-royalty structure (specific royalty-rate split not publicly disclosed) to fund development, regulatory approval, and commercial launch of ANG003, an oral recombinant non-porcine enzyme replacement therapy for exocrine pancreatic insufficiency in cystic fibrosis.

Transaction summary

Term	Detail
Issuer	Anagram Therapeutics, Inc. (private; Cambridge MA)
Investor	Blackstone Life Sciences (BXLS)
Investment amount	$250M
Structure	Hybrid equity + royalty (BXLS Capital Partners V structured-investment template)
Lead asset	ANG003 — oral recombinant non-porcine ERT
Indication	Exocrine pancreatic insufficiency in cystic fibrosis (CF EPI)
Prior funding	>$30M from the Cystic Fibrosis Foundation Therapeutics Development Awards

Why this matters

One of BXLS's largest single 2026 biotech investments to date — ranks alongside Moma Therapeutics ($150M+) and Anthos Therapeutics deployments in BXLS Capital Partners V's CF/rare-disease pocket
CF EPI is a $1B+ category historically dominated by porcine-derived pancrelipase products (AbbVie's Creon, Nestlé/Allergan Zenpep, Vivus Pancreaze, Digestive Care Pertzye); first non-porcine recombinant oral ERT would address vegan/halal/kosher patient populations + supply security concerns + dose precision
BXLS's hybrid equity+royalty template here is structurally similar to the Alnylam ($2B; April 2020), Anthos ($250M; 2019), and Vivos Therapeutics ($150M; 2024) precedents; the operative innovation is structured equity with royalty optionality on commercialization
Read-through to broader 2026 royalty-finance landscape: late-stage rare-disease assets with established clinical hubs (CF Foundation Therapeutics Development Awards) are pricing at premium structured-finance multiples; BXLS, RA Capital structured, and Royalty Pharma RIDS deals now represent three parallel late-stage non-dilutive structures
Pancreatic insufficiency franchise also relevant to broader pancreatic-enzyme royalty-stack landscape (Aimmune Therapeutics historical Palforzia comp; Sunovion consumption-economics)

Lexicon Pharmaceuticals / Hercules Capital Senior-Secured Term Loan (Mon 4 May close; 8-K Wed 6 May)

Up to $100M senior-secured term loan facility (3 tranches) from Hercules Capital, replacing existing Oxford Finance loan. Lexicon (NASDAQ: LXRX) closed Tranche 1 of $55M on Monday 4 May; balance available on milestones.

Facility terms

Term	Detail
Aggregate facility	Up to $100M (3 tranches)
Tranche 1 (funded at close)	$55M — used to repay existing Oxford Finance senior-secured loan (full payoff)
Tranche 2 (milestones-conditional)	Up to $20M, drawable on revenue/clinical milestones
Tranche 3 (Hercules-consent)	Up to $25M, drawable thereafter with Hercules consent
Interest rate	Floating: prime + 3.10%; 9.85% floor
Interest-only period	18 months with two 6-month extensions
Maturity	4 May 2030
Security	First lien on substantially all assets
Covenants	Minimum cash covenant from 1 June 2027

Read-through

Refinancing structure is the operative event — Lexicon swaps Oxford Finance facility for Hercules with extended runway + milestone-tranching optionality; characteristic of mid-cap commercial-stage biotech pharma-credit refinancing template
9.85% floor is consistent with mid-2026 pharma-credit pricing benchmarks; sits ~100-150bps below comparable Pharmakon (BioPharma Credit) senior-secured pricing on equivalent commercial-stage names
Two 6-month IO extensions provide ~30-month cumulative IO runway — meaningful if Inpefa (sotagliflozin) HFmrEF/HFpEF expansion timeline slips relative to current FDA timing
Lexicon's choice of Hercules over Pharmakon, K2 HealthVentures, or Oxford continuation reflects ongoing pharma-credit pricing competition; Hercules now has positions in Lexicon, Citius (W19), Cyclerion, and Vor Bio across the 2026 origination cycle
Read-through to Lexicon shareholders: non-dilutive runway extension to 1H 2028+, supportive of completed Inpefa HF launch + Phase 3 LX9211 (DPN) data readout 2027

Citius Oncology / Avenue Venture Opportunities Fund II (Tue 5 May)

Up to $36.5M combined: $25M senior-secured term loan + ~$11.5M warrant-exercise proceeds. Citius Oncology (CTOR; NASDAQ) secured non-dilutive growth capital for LYMPHIR™ (denileukin diftitox-cxdl) commercial expansion in r/r cutaneous T-cell lymphoma (CTCL).

Facility terms

Term	Detail
Lender	Avenue Venture Opportunities Fund II
Term loan	Up to $25M total
Tranche 1 (close)	$10M
Tranche 2 (milestone)	Up to $15M, conditional on revenue + liquidity milestones
Term	3.5 years
Concurrent	Warrant exercise proceeds ~$11.5M
Placement agent	H.C. Wainwright & Co.
Use of proceeds	LYMPHIR US commercial scale-up + Phase 3 expansion

Read-through

Citius / Avenue facility extends Citius's commercial runway through LYMPHIR's first full year of US launch (FDA-approved August 2024)
Avenue Venture Opportunities Fund II remains an active venture-debt counterparty in commercial-stage biotech (recent: Connect Biopharma 2025, Ocean Biomedical 2024); positioned in the mid-tier of the venture-debt market alongside Hercules, K2 HealthVentures, and SLR Investment
Combined $36.5M (debt + warrants) materially below Citius's prior $50M+ targets; reflects challenging mid-cap commercial-stage financing market and small CTCL TAM (~3,000 US patients)
LYMPHIR royalty obligation profile (Eisai upstream royalty on denileukin diftitox legacy IP) sits behind the Avenue first-lien position

Orchestra BioMed / Ligand Royalty Financing — Final Tranche (Mon 6 May)

$15M final tranche from Ligand Pharmaceuticals (LGND) under the August 2025 Revenue Participation Right Purchase and Sale Agreement (RIPA), bringing Ligand's total commitment to $35M. Cash received 1 May; announcement 6 May.

Aggregated transaction summary

Term	Detail
Counterparty	Ligand Pharmaceuticals (LGND) as royalty buyer
Originator	Orchestra BioMed Holdings (OBIO)
Original framework	August 2025 Revenue Participation Right Purchase & Sale Agreement
Aggregate Ligand commitment	$35M
First tranche (Aug 2025)	$20M
Final tranche (May 2026, this transaction)	$15M (cash received 1 May; 8-K disclosed 6 May)
Royalty asset	Tiered royalty interest on AVIM Therapy + Virtue SAB cardiovascular programs
AVIM partner	Medtronic (BiVACOR exclusive worldwide license; pacemaker-class hypertension indication)
Virtue SAB partner	Terumo (worldwide ex-China; sirolimus-eluting balloon for in-stent restenosis)

Read-through

Ligand's RIPA-style royalty acquisitions sit alongside its traditional license origination + Pelthos / Brisbane Royalty Aggregator as a third operating mode for the company
Royalty interest spans two distinct medical-device-driven cardiovascular royalty layers — uncommon two-asset RIPA structure; reduces Ligand's idiosyncratic single-asset royalty risk vs. its historical pattern (Captisol, Filspari, Vaxneuvance)
Read-through to OBIO: completes financing for Phase 2 BACKBEAT (AVIM in HF) + Phase 3 Virtue ISR-2 (Virtue SAB pivotal); de-risks 2H 2026 / 2027 development funding
For Ligand royalty-aggregator platform thesis (Brisbane Royalty Aggregator framework + recent BRY/CFB rotation), the OBIO completion confirms continuing Ligand commitment to mid-cap medical-device-adjacent royalty origination

Capricor Therapeutics v. Nippon Shinyaku / NS Pharma — Rescission Lawsuit (Thu 7 May)

Capricor Therapeutics (NASDAQ: CAPR) filed suit in New Jersey Superior Court seeking rescission of the 2022 deramiocel (CAP-1002) US distribution agreement with NS Pharma, the US subsidiary of Japan's Nippon Shinyaku. The lawsuit lands 3.5 months ahead of the deramiocel PDUFA action date of 22 August 2026 for Duchenne muscular dystrophy cardiomyopathy.

Background — original 2022 transaction

Term	Detail (per 2022 announcement)
Counterparty	NS Pharma, Inc. (US subsidiary of Nippon Shinyaku, Tokyo)
Asset	Deramiocel (CAP-1002) — allogeneic cardiosphere-derived cells for DMD cardiomyopathy
Geographic scope	United States (commercial distribution + commercialization)
Upfront	$30M
Aggregate milestones	Up to $705M ($705M aggregate development + regulatory + commercial milestones disclosed 2022)
Royalties	Tiered royalties (rate not publicly disclosed)

W19 dispute — Capricor allegations

"Fundamental pricing flaw" in the agreement makes Medicare / Medicaid economics unviable for the DMD cardiomyopathy commercial launch
Capricor seeks rescission of the agreement (not damages), which would return all US commercial rights to Capricor pre-PDUFA
Filing in NJ Superior Court rather than via JAMS or AAA arbitration — implies Capricor is taking a public-litigation stance rather than confidential dispute resolution
CAPR closed -13% after-hours following the disclosure; market is interpreting this as significant launch-readiness disruption ahead of PDUFA

Read-through

PDUFA Aug 22, 2026 is the critical event; if FDA approves deramiocel, the rescission lawsuit becomes substantially more valuable to Capricor (full US commercial economics retained) — but also significantly more contentious for NS Pharma / Nippon Shinyaku
For royalty-finance / synthetic-royalty market: deramiocel is a credible 2026/2027 royalty-monetization candidate post-approval; rescission-driven uncertainty creates bid-ask spread on any pre-launch royalty trade
Cross-border Japan-US deal contract-rescission events are uncommon — limited precedent (last comparable: Astellas / Cytokinetics 2021 omecamtiv termination); template for future Japanese strategic dispute resolution
Read-through to Nippon Shinyaku Q1 results (mid-May): exposure to deramiocel write-down possible if rescission succeeds; Japanese strategic capital allocation in US biotech may face heightened due-diligence on Medicare/Medicaid pricing scenario analysis

Ligand Pharmaceuticals Termination of Viking Therapeutics TR-Beta License (effective Mon 4 May)

Ligand Pharmaceuticals (LGND) terminated the May 2014 Master License Agreement covering Viking Therapeutics' (VKTX) TR-Beta program — i.e., VK2809 (MASH/MASLD) and VK0214 (X-ALD). Termination effective Mon 4 May (notice issued 24 April). Viking publicly disputes Ligand's right to terminate.

Transaction summary

Term	Detail
Original agreement	Master License Agreement, May 2014
Licensor	Ligand Pharmaceuticals (LGND)
Licensee	Viking Therapeutics (VKTX)
Programs licensed	TR-Beta thyroid hormone receptor agonists
Lead asset	VK2809 (Phase 2/3 MASH/MASLD; HoFH program ongoing)
Secondary asset	VK0214 (Phase 1b adrenoleukodystrophy / X-ALD)
Notice issued	24 April 2026
Effective	4 May 2026
Cited grounds	Contract breach (Viking development-conduct allegations)
Termination remedy sought	Non-exclusive worldwide royalty-bearing license to Viking-controlled patent rights

Why this matters

Material royalty-stream implications for one of Ligand's signature legacy 2014 license positions; VK2809 is among Viking's most advanced clinical assets (Phase 2 MASH topline 2H 2026)
Viking publicly disputes Ligand's right to terminate — the dispute is not settled and will likely require arbitration / litigation; the operative question is whether Ligand's grounds for termination are contractually permissible
For Ligand royalty income outlook: best-case scenario (termination upheld + non-exclusive license retained) preserves Ligand's contingent royalty optionality on VK2809; worst-case (Viking prevails + license retained) preserves status quo (existing tiered royalty terms) but with strained counterparty relationship
Viking shareholders face contract-overhang risk; VKTX implied royalty-burden uncertainty likely depresses 2026 forward EBITDA multiples until dispute resolution
Read-through to Ligand royalty origination strategy: Ligand has reactivated dispute-driven license-management — characteristic of late-stage royalty franchises where original 2014-era terms no longer reflect 2026 commercial economics; potentially template for future Filspari, Vaxneuvance, or Captisol disputes

Genmab Q1 2026 Royalty Disclosure (Thu 7 May)

Royalty revenue $742M (+26% YoY) — largest pure-play royalty income disclosure of W19. Genmab (NASDAQ: GNMB; CSE: GMAB) reported Q1 2026 financials before-market on Thursday 7 May, with royalty income materially driven by DARZALEX (J&J) and Kesimpta (Novartis).

Q1 2026 royalty income breakdown

Royalty asset	Counterparty	Disclosed Q1 2026
DARZALEX (daratumumab; multiple myeloma)	Janssen / J&J	DARZALEX net sales $3.964B (+22% YoY); Genmab 12-20% tiered royalty
Kesimpta (ofatumumab; relapsing MS)	Novartis	Kesimpta included in Q1 royalty pool
Aggregate Genmab royalty revenue	Multiple	$742M (+26% YoY from $589M)

Why this is the most significant W19 royalty earnings print

$742M Q1 royalty revenue substantially exceeds RPRX's $887M Q1 royalty receipts (although RPRX has a more diversified royalty pool); Genmab is the largest pure-play single-quarter royalty originator in 2026 outside of Royalty Pharma itself
DARZALEX is now a $15B+ run-rate franchise with Genmab royalty exposure; ranks alongside Alnylam Leqvio, GSK Trelegy, and BMS Eliquis as top-5 single-asset 2026 royalty income contributors globally
Kesimpta inclusion is structurally important — Genmab's pre-IPO HuMax-CD20 platform spawned both DARZALEX (J&J) and Kesimpta (Novartis), making Genmab the operative example of a multi-licensee royalty platform (vs. single-asset originators)
For Genmab equity holders: $742M Q1 royalty revenue at ~50% gross margin contribution implies >$1.5B FY26 royalty contribution — supports the company's pivot toward in-house product launches (Tepkinly, Rina-S, Tivdak) without compromising legacy royalty cash flows
Read-through to broader 2026 royalty-finance market: Genmab demonstrates the multi-decade monetization potential of platform-derived antibody royalties — a comp for emerging royalty stacks at Adaptive (Amgen), Alector (GSK), and Cygnal (Eli Lilly)

Abivax Royalty Certificate Repurchase (Tue 5 May; closing on/about Thu 7 May)

$90M reverse royalty transaction — Abivax (NASDAQ: ABVX; obefazimod / UC) repurchases and cancels all outstanding royalty certificates originally issued September 2022. Uncommon issuer-side reverse-royalty structure worth tracking as a 2026 reference comp.

Transaction summary

Term	Detail
Issuer	Abivax SA (NASDAQ: ABVX; Euronext: ABVX)
Sellers	TCG Crossover, Venrock Healthcare Capital Partners, Deep Track, Sofinnova Crossover, Invus, FPCI BioMedTech, Santé Holdings
Aggregate consideration	$90M total
Cash	$45M
Equity	$45M via 403,347 ADSs at $111.57 (interest-free vendor-loan set-off mechanism)
Original issuance	September 2022 royalty certificates linked to obefazimod (UC)
Effect	Cancels all royalty certificates → eliminates royalty overhang ahead of obefazimod commercial launch
Dilution	~0.5%

Read-through

Reverse royalty transactions (issuer buying back royalty obligations) are uncommon and structurally distinct from royalty originations; this is the cleanest 2026 disclosed comparable for pre-launch royalty-overhang cleanup ahead of commercial inflection
50/50 cash/ADS split with vendor-loan set-off allows Abivax to preserve cash runway while clearing the royalty stack — a replicable structure for other late-clinical-stage issuers with restrictive royalty obligations
Read-through to broader issuer-side royalty unwind market: Gilead's W19 Q1 disclosure (next section) referenced expiration of a Trodelvy-era royalty obligation contributing 200bps non-GAAP gross margin expansion — different mechanism (natural expiration vs. negotiated repurchase) but same directional issuer outcome
ABVX cap structure post-repurchase substantially de-risked → credible late-2026 / 2027 royalty monetization candidate (cf. Royalty Pharma's pattern of pre-launch tier deployments)

Gilead Q1 2026 Disclosures (Thu 7 May, after-close)

Single most BD-information-dense large-cap Q1 call in the W19 window. Gilead's call confirmed economics on three previously-light-on-detail transactions plus a previously-undisclosed Genhouse Bio deal plus a Trodelvy-era royalty obligation expiration.

Net-new disclosures

Transaction	Status	Economics confirmed Q1 call
Tubulis acquisition	Pending (Q2 close)	~$3.2B upfront cash + up to $1.9B contingent milestones (TUB-040 NaPi2b topo-I ADC)
Ouro Medicines acquisition	Pending (Q2 close)	~$1.7B upfront + up to $500M milestones (T-cell engager autoimmune)
Arcellx (closed Q1)	Closed	$115/sh + 1 CVR @ $5/sh = ~$7.8B equity value; eliminates anito-cel profit-share; BLA accepted, PDUFA 23 Dec 2026
Genhouse Bio license (newly disclosed)	In effect Q1	"~$107M Q1 IPR&D primarily driven by upfront payment for Genhouse Bio" (CFO Andrew Dickinson on call); previously low-profile transaction
Royalty obligation expiration	Effective	Non-GAAP product gross margin +200bps to 87.5%, attributed to "expiration of a royalty-related obligation" (likely Trodelvy / Immunomedics legacy royalty layer)
Trodelvy Q1	Reported	Q1 sales $402M, +37% YoY

Read-through

Combined Q2 IPR&D charge ~$11.5B from Tubulis + Ouro closes; reduces 2026 non-GAAP EPS guidance by ~$9.50/share
Tubulis $3.2B + $1.9B economics confirm Lonza/SYNtecan + Halozyme/GSK ENHANZE-ADC W19 deals are part of a broader 2026 ADC platform-licensing supercycle; Tubulis Tubutecan + P5 platform now has BMS (2023, $22.75M up + $1B+) and Gilead (2026, $3.2B + $1.9B) as anchor licensees
Gilead's Trodelvy royalty-obligation expiration is the second royalty-overhang cleanup event of W19 alongside Abivax (above) — issuer-side royalty unwinds emerging as a 2026 theme distinct from origination flow
Genhouse Bio disclosure is genuinely net-new — license terms remain undisclosed but ~$107M Q1 IPR&D suggests upfront alone in the $100M+ range, putting Genhouse in the upper tier of 2026 China-out-licensing comps

BeOne Medicines / Huahui Health HH160 Trispecific Option (Wed 6 May, Q1 disclosure)

BeOne (formerly BeiGene) disclosed in its Q1 2026 release (Wed 6 May) a new exclusive option to license worldwide rights to HH160 (BON-110), a novel trispecific antibody targeting PD-1 + VEGF-A + CTLA-4 from China's Huahui Health.

Transaction summary

Term	Detail
Optionee	BeOne Medicines Ltd. (NASDAQ: ONC)
Optionor	Huahui Health (China)
Asset	HH160 / BON-110 — trispecific PD-1 × VEGF-A × CTLA-4
Structure	Exclusive option to license worldwide rights
Economics	Upfront / milestones / royalties not disclosed in Q1 release
Disclosure	BeOne Q1 2026 earnings release Wed 6 May

Read-through

Third W19 China out-licensing-into-Western-pharma deal alongside GSK / SiranBio (siRNA, Wed) and Kelun-Biotech / MSD sac-TMT NMPA expansion (Fri); confirms 2026 China outbound BD cadence remains structurally elevated
Trispecific PD-1 / VEGF-A / CTLA-4 mechanism extends the Akeso/Summit ivonescimab (PD-1 × VEGF) franchise into a third payload (CTLA-4); if HH160 reads out positively, BeOne positions as direct global commercialization counterparty to ivonescimab class
Confirms BeOne's pivot from US-China-bridge importer (legacy BeiGene model) to independent global oncology platform with active in-licensing capability
Same Q1 release also confirmed Royalty Pharma Imdelltra arrangement is being accounted for as financing-liability with $25–50M FY26 interest amortization

Capital Markets (W19)

W19 was one of the busiest biotech capital-markets weeks of 2026. Aggregate fresh equity / structured capital priced or closed across the window came to approximately $3.2B, with Mon 4 May the busiest single day (~$1.04B) and Wed 6 May the largest readout-driven day. Three structural themes stand out: (1) post-readout follow-ons clustering in the same week as positive trial data (Avalo post-AVTX-009 Tue; Viridian post-REVEAL-2 Wed; Cytokinetics post-ACACIA-HCM Wed/Fri close); (2) debt + RIPA + structured-finance origination cadence in the mid-cap commercial-stage pocket; and (3) continued cross-border crossover capacity (Windward Bio Swiss; Cytospire UK Servier Ventures debut; Latus Bio US-Korea Development Bank).

Public follow-ons + registered directs

Issuer (ticker)	Date	Size
Aura Biosciences (AURA)	Mon 4 May	$260.3M gross
Cabaletta Bio (CABA)	Mon 4 May	$150M / ~$141M net
Avalo Therapeutics (AVTX)	Tue 5 May	$375M
InflaRx (IFRX)	Thu 7 May	$150M
Cytokinetics (CYTK)	Priced Wed 7 May / closed Fri 8 May	~$700M gross

Aura Biosciences priced 39.59M sh @ $6.00 + 3.8M PFW (~$205M to bel-sar; Matrix $39M secondary @ $5.64) with Leerink / TD Cowen / Evercore.

Cabaletta Bio priced 51.725M sh @ $2.90 with TD Cowen / Guggenheim / Cantor (book-runners) and H.C. Wainwright (lead manager); Bain Life Sciences, Adage, Cormorant, and Lilly participated; runway extended into mid-2027.

Avalo Therapeutics priced at $17.75 immediately post-AVTX-009 Phase 2 HS positive readout (HiSCR75 42.9%; AVTX +18% on the day). Joint book-runners Leerink / TD Cowen / BofA / Piper Sandler / Cantor Fitzgerald. Largest single biotech follow-on of W19.

InflaRx priced 75M ordinary shares at $2.00 with Guggenheim Securities (lead bookrunner), Oppenheimer + LifeSci Capital (bookrunners), Raymond James + Needham (co-leads), and HC Wainwright + Lucid Capital Markets (co-managers). Mintz advised the underwriters; investor syndicate included TCGX, Farallon, Sirenia, Columbia Threadneedle, Great Point, ADAR1, Coastlands, and Squadron.

Cytokinetics priced 9.86M sh × $71.00 with a 1.48M-sh greenshoe; Morgan Stanley / Goldman Sachs / J.P. Morgan / Jefferies joint book-runners. The raise was driven by ACACIA-HCM Phase 3 success in nHCM; RPRX is the direct counterparty (aficamten royalty), and the close materially de-risks RPRX's largest near-term royalty contributor.

Convertibles + concurrent offerings

Issuer (ticker)	Date	Size
Ocugen (OCGN)	Mon 4 May	$115M (+$15M opt)
Travere Therapeutics (TVTX)	Wed 6 May	$475M
Viridian Therapeutics (VRDN)	Wed 6 May	$350M aggregate (~$334.7M net)

Ocugen issued $115M convertible senior notes due 2034 (144A) + $15M option; conversion price and coupon TBD.

Travere Therapeutics priced $475M convertible senior notes due 2032 (upsized from $400M; +$60M option) at 0.50% coupon with ~45% conversion premium off $44.76 reference. JPM / Jefferies / Leerink joint book-runners. Critical context for royalty-finance audiences: Travere drives Filspari (sparsentan), which is Ligand's largest current royalty-asset contributor; Travere's debt-financing capacity decisions impact Ligand royalty income forecast directly. Convert proceeds for general corporate, working capital, and capped-call hedging.

Viridian Therapeutics priced concurrent offerings: $225M 1.75% convertible senior notes due 2032 + $125M equity (7.35M sh @ $17.00). Jefferies / Leerink / Goldman Sachs joint book-runners. Proceeds repay the existing Hercules Capital senior-secured loan and fund TED franchise expansion (post-REVEAL-2 success). DRI Healthcare's $300M synthetic-royalty position remains the operative downstream royalty-finance lever on Viridian.

Debt + structured financings

Issuer (ticker)	Date	Size
Lexicon Pharmaceuticals (LXRX)	Mon 4 May	Up to $100M (3 tranches)
Citius Oncology (CTOR)	Tue 5 May	Up to $36.5M combined
Cellectar Biosciences (CLRB)	Tue 5 May	Up to $140M
Anagram Therapeutics (private)	Thu 7 May	$250M

Lexicon / Hercules Capital senior-secured term loan: $55M Tranche 1 funded at close (used to repay existing Oxford Finance facility); up to $20M Tranche 2 milestone-conditional + up to $25M Tranche 3 with Hercules consent. Floating prime + 3.10% / 9.85% floor; 18-month IO with two 6-month extensions; maturity 4 May 2030. 8-K Wed 6 May. See dedicated Lexicon / Hercules section for full read-through.

Citius Oncology / Avenue Venture Opportunities Fund II: $25M senior secured term loan ($10M at close + up to $15M milestone-conditional; 3.5-year term) plus ~$11.5M warrant-exercise proceeds. H.C. Wainwright placement agent. Funds LYMPHIR (denileukin diftitox-cxdl) US commercial scale-up in r/r CTCL.

Cellectar Biosciences: registered direct + concurrent private placement structure (~$35M upfront + up to ~$105M milestone-based warrants — milestone-tranched PIPE structure is noteworthy). Lead Nantahala Capital (board seat for Andrew Gu); Balyasny, Caligan, Janus Henderson, SilverArc, Stonepine, Stempoint, and Empery participating. Funds Q4 2026 confirmatory pivotal trial + NDA pursuit (accelerated approval) for iopofosine I-131 in Waldenström macroglobulinemia.

Anagram Therapeutics / Blackstone Life Sciences: $250M structured investment (hybrid equity + royalty) for ANG003 oral non-porcine ERT for CF EPI. One of BXLS's largest single 2026 biotech investments. See dedicated Anagram / Blackstone section.

PIPEs

Issuer (ticker)	Date	Size
CNS Pharmaceuticals (CNSP)	Mon 4 May	$22.5M
Cue Biopharma (CUE)	Mon 4 May	$30M

CNS Pharmaceuticals PIPE: 650k common + 9.14M PFW @ $2.30; ADAR1, Ikarian, Stonepine, Nazare; A.G.P. agent.

Cue Biopharma PIPE: pre-funded warrants + warrants at $11.00/unit; Newbridge Securities placement agent. Concurrent with the Cue / Ascendant Health Sciences Ascendant-221 ex-Greater China license (initial closing on/about Mon 4 May).

IPOs (priced + debuts)

Issuer (ticker)	Pricing date	Debut	Size
Hemab Therapeutics (COAG)	30 Apr	Closed 4 May	$346.7M
Seaport Therapeutics (SPTX)	30 Apr	Closed 4 May	$254.9M
Odyssey Therapeutics (ODTX)	Priced Thu 7 May	Debut Fri 8 May	~$304M gross
Mobia Medical (MOBI)	Priced Thu 7 May (eve)	Debut Fri 8 May	$150M

Hemab Therapeutics: 19.26M sh @ $18.00 with full greenshoe; Goldman / Jefferies / Evercore ISI (book-runners), Wedbush PacGrow lead manager.

Seaport Therapeutics: 14.16M sh @ $18.00; PureTech retains ~16.7M sh; Goldman / JPM / Leerink / Citi / Stifel.

Odyssey Therapeutics: $279M IPO (15.5M sh @ $18.00) + $25M concurrent PIPE to TPG Life Sciences Innovations = ~$304M gross; ~$810M+ market cap. JPM / TD Cowen / Cantor (book-runners); Wedbush PacGrow + Oppenheimer (co-lead managers). Lead assets OD-001 (RIPK2/UC) and OD-002 (SLC15A4).

Mobia Medical: priced Thu evening at $15.00; began trading on Nasdaq Global Select Fri 8 May. Commercial-stage neuro-recovery medical device (formerly MicroTransponder).

ATM / repurchase / ASR

Issuer (ticker)	Date	Size
BridgeBio Pharma (BBIO)	Thu 7 May	$500M ATM + $500M repurchase authorized
Indivior (INDV)	Mon 4 May	$175M ASR

BridgeBio Pharma: ATM offering capacity authorized concurrent with $500M share repurchase program. Goldman Sachs / Leerink Partners. Net effect: financing optionality + signaling of Acoramidis (ATTR-CM) launch progress.

Indivior: $175M ASR with Barclays. 3.7M sh delivered up front; $100M remaining.

Private rounds: crossover + Series A/B/C/D

Company (HQ)	Date	Size
Windward Bio (Switzerland)	Mon 4 May	$165M crossover
Latus Bio (US)	Mon 4 May	$97M Series A
Cytospire Therapeutics (UK)	Tue 5 May	£61M / ~$83M Series A
CellCentric (UK / US)	Wed 6 May	$220M Series D
Kanvas Biosciences	Wed 6 May	$48M Series A
LTZ Therapeutics	Wed 6 May	$38M (structure undisclosed)

Windward Bio: OrbiMed-led; new investors RA Capital Management, Janus Henderson, Sanofi Ventures, Harbour BioMed; existing Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture, Quan Capital, Pivotal bioVenture Partners. Homburger legal counsel. Long-acting biologics for inflammatory and respiratory disease; lead WIN378 anti-TSLP (Phase 2 severe asthma).

Latus Bio: 8VC-led; participation from DCVC Bio, BioAdvance, Benjamin Franklin Tech Partners, Modi, Gaingels, Hatch BioFund. New: Korea Development Bank + Helen's Pink Sky Foundation — first major Korean strategic capital into a US AAV play. AAV gene therapy; LTS-201 Huntington's (IND Q3 2026), LTS-101 CLN2 Batten.

Cytospire Therapeutics: oversubscribed; led by 4BIO Capital. Debut investment from Servier Ventures' newly launched corporate venture fund. Also Sound Bioventures, British Business Bank (£12M anchor), Criteria Bio Ventures, Modi, Medical Incubator Japan, Pathway Bioventures, with existing Abingworth and LifeArc Ventures. Pan-γδ T-cell engagers; lead CYT X300 in EGFR+ solid tumors.

CellCentric: oversubscribed; Venrock Healthcare Capital Partners-led. New investors Fidelity, Sofinnova Partners, HBM Healthcare; existing RA Capital, Forbion, Pfizer, Avego, BrightEdge. Largest disclosed European private biotech raise of 2026. Funds global Phase 3 DOMMINO-2 of inobrodib (oral first-in-class p300/CBP inhibitor) in r/r multiple myeloma + ongoing Ph2 DOMMINO-1. >500 patients dosed across program; >2x response rate vs historic alternatives in heavily pretreated RRMM (median 5 prior lines) per ASH 2025 data.

Kanvas Biosciences: KAN-001 live biotherapeutic for solid organ cancer; cancer microbiome therapeutics angle.

LTZ Therapeutics: LTZ-301 CD79b bispecific antibody (Ph1 R/R NHL); Universal Myeloid Cell Engager platform.

Private rounds: seed

Company (HQ)	Date	Size
Brano Therapeutics (Singapore)	Wed 6 May	$6.8M seed
ParcelBio (SF)	Thu 7 May	$13M seed
Scarlet Therapeutics (UK)	Thu 7 May	£3.2M / ~$4M seed

Brano Therapeutics: Duke-NUS Medical School spin-out; led by Trinity Innovation Bioventure Singapore + SEEDS, with SGInnovate and Duke-NUS LIVE Ventures' first-ever direct spin-off investment ($380K). Small-molecule HFpEF cardiac metabolic regulator; clinic by 2029.

ParcelBio: Breyer Capital-led; participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC. APEXm™ (Amplified and Prolonged EXpression mRNA) platform; lead in vivo CAR-T for autoimmune (B-cell-mediated). ASGCT oral debut 14 May 2026.

Scarlet Therapeutics: biotech therapeutics manufacturing platform; full syndicate not in surfaced disclosure.

Additional Clinical & Regulatory Readouts (Tue–Thu)

Multiple positive Phase 2/3 clinical readouts and regulatory developments outside the W19 deal flow proper, consolidated here for completeness. Royalty-finance read-throughs noted in the post-table prose where relevant.

Phase 3 / Phase 3b readouts

Sponsor (ticker)	Asset	Date / venue
Incyte (INCY)	Opzelura (ruxolitinib cream)	Thu 7 May, EADV Symposium Athens
Sebela / Braintree Labs (private)	Tegoprazan (P-CAB)	Tue 5 May, DDW 2026

Incyte Opzelura — TRuE-AD4 24-week long-term data. Among Week 8 EASI50 responders continuing through Week 24 in adult moderate atopic dermatitis: 84.3% achieve EASI75; 70.6% IGA-Treatment Success. Supports EU Type-II MAA variation for moderate AD label expansion; feedback expected 1H 2026. Royalty-finance read-through: the historical Lilly low-single-digit royalty layer on certain Opzelura sales (per the legacy 2009 Incyte / Lilly collaboration) extends to any EU moderate-AD label expansion if granted.

Sebela / tegoprazan — Phase 3 TRIUMpH-EE topline. Tegoprazan (P-CAB; ex-HK Inno.N origination) demonstrated superiority to lansoprazole in healing all-grade EE at Week 2 + Week 8, in 24-week maintenance, and in heartburn relief in severe LA Grade C/D patients. P-CAB class continuing to print positive Phase 3 data; tegoprazan now head-to-head positive vs. PPI standard-of-care; potential US NDA pathway 2027.

Phase 2 readouts

Sponsor (ticker)	Asset / mechanism	Date / venue
ISOThrive (private)	MHS-1031 (microbiome-based GERD therapy)	Tue 5 May, DDW 2026
MingMed Biotechnology (private; China)	QA102 (oral)	Tue 5 May, ARVO 2026 Denver
Medicus Pharma (MDCX)	D-MNA / SkinJect (doxorubicin Microneedle Array)	Wed 6 May

ISOThrive MHS-1031 in NERD. Highly statistically significant reductions in heartburn incidence / severity and regurgitation in PPI-incomplete responders. NERD is ~70% of GERD's 45M US adult population — large potential commercial TAM.

MingMed QA102 in dry AMD — mixed / missed primary. Mean drusen volume change not statistically significant (numerical 59.2% reduction vs. placebo). Secondaries positive: drusen volume growth rate −118.2% (p=0.017); √-transformed GA area growth −42.7% (p=0.026) in 400 mg arm. Plans to advance — ambiguous Phase 3 path.

Medicus Pharma SKNJCT-003 expanded dataset in nodular BCC. Positive dose-response: 55% complete response at Day 57 in 200µg cohort (registrational-grade lead dose). Final CSR Q2 2026; supports End-of-Phase 2 meeting + partnering discussions. Royalty-finance read-through: drug-device combo product class adjacent to MannKind DPI franchise; potential Phase 3 / out-license candidate.

Regulatory

Sponsor (ticker)	Event	Date
Nuvation Bio (NUVB)	sNDA acceptance for IBTROZI (taletrectinib) in advanced ROS1+ NSCLC	Wed 6 May
Nanobiotix / J&J	NANORAY-312 protocol amendment accepted by FDA	Mon 4 May

Nuvation Bio IBTROZI sNDA acceptance. Target action date 4 January 2027. Updated TRUST-I (TKI-naïve): mDOR 49.7 mo / mPFS 49.6 mo; TRUST-II (TKI-pretreated): mDOR 19.4 mo. Concurrent AACR 2026 update. Mechanically additive to the existing taletrectinib commercial label (already approved 1L ROS1+ NSCLC June 2025); the duration-of-response update is a label-strengthening event ahead of payer negotiations.

Nanobiotix / J&J NANORAY-312. FDA accepts Phase 3 protocol amendment for JNJ-1900 (NBTXR3) — radiotherapy-activated hafnium oxide nanoparticles in platinum-ineligible LA HNSCC. Amendment removes pre-planned interim analysis; final analysis brought forward — could accelerate global registration timeline. J&J assumed pivotal sponsorship in 2024 under the earlier Nanobiotix licensing agreement.

Friday May 8 — Thin-Day Catalysts

W19 closes with no new BD or M&A announcements. One headline FDA approval (Partner Therapeutics Bizengri — first-ever in NRG1+ cholangiocarcinoma), three regulatory / clinical items, five mechanical events.

Bizengri (zenocutuzumab-zbco) Full sBLA Approval — Partner Therapeutics

First-ever drug approved for NRG1+ cholangiocarcinoma — single most significant regulatory event of W19. Partner Therapeutics, Inc. (Lexington MA; private specialty oncology commercial) received full sBLA approval of Bizengri (zenocutuzumab-zbco) in advanced unresectable / metastatic NRG1 fusion-positive cholangiocarcinoma post systemic therapy. The approval came under the 7th Commissioner's National Priority Voucher (CNPV) pilot, with the voucher granted Wed 6 May enabling 1–2 month review (vs. standard 10-month sBLA cycle).

Key facts

Item	Detail
Approval date	Friday 8 May 2026
Sponsor	Partner Therapeutics, Inc. (PTx)
Drug	Bizengri (zenocutuzumab-zbco)
Mechanism	HER2/HER3 bispecific antibody (Merus Biclonics® / Dock & Block® platform); blocks NRG1 fusion-driven HER3 signaling
W19 indication	NRG1+ cholangiocarcinoma post systemic therapy (advanced unresectable / metastatic)
Pivotal data	Phase 1/2 eNRGy trial: 36.8% ORR; DOR 2.8–12.9 months
Approval pathway	7th Commissioner's National Priority Voucher (CNPV) pilot
Prior approvals	Dec 2024 accelerated approval in NRG1+ NSCLC + pancreatic adenocarcinoma
Prior designations (cholangio)	Breakthrough Therapy (Oct 2025) + Orphan Drug (Feb 2026)

Bizengri (zenocutuzumab) royalty stack

Layer	Counterparty	Economics
Origin / IP holder	Merus N.V. (Nasdaq: MRUS; Utrecht, NL)	Biclonics® / Dock & Block® bispecific antibody platform
US commercial license (Nov 27, 2024)	Merus → Partner Therapeutics, Inc. (PTx)	Exclusive sublicensable royalty-bearing license for NRG1+ cancer in US; PTx funds dev / mfg / clinical / companion Dx; limited non-exclusive royalty-bearing OUS license for named patient program until Merus pursues OUS approval
Upfront paid	PTx → Merus	Undisclosed upfront cash payment
Milestones	PTx → Merus	Up to $130M in milestone payments tied to commercial success of zenocutuzumab
Royalties	PTx → Merus	High-single-digit to low-double-digit (HSD-LDD) tiered royalties on annual US net sales of Zeno in NRG1+ cancer
Sales-target reversion clause	If PTx fails to meet sales targets in Year 3 + Year 4 post-launch	Merus retains right to terminate agreement with rights reverting to Merus

Read-through

The Bizengri W19 cholangiocarcinoma approval directly accelerates Merus royalty cash flows from PTx, with the cholangiocarcinoma label expansion adding a third revenue line (NSCLC + pancreatic + cholangiocarcinoma) to the existing PTx royalty obligation. Because the license is US-only, OUS commercialization remains under Merus control with potential additional ex-US licensee economics on the table. PTx's $130M milestone obligation + HSD-LDD royalty profile makes Merus a credible 2027/2028 synthetic-royalty origination candidate, akin to Genmab DARZALEX or BeiGene tislelizumab royalty-monetization comps. The 7th CNPV approval also continues the broader acceleration of FDA priority-voucher use (recent: Geron Phazyr, Madrigal Rezdiffra label expansions); Partner Therapeutics' Bizengri label expansion ranks alongside Astellas/Veozah and Iovance/Amtagvi as 2024-2026 small-cap rare-cancer commercial launches.

Rznomics RZ-001 RMAT Designation (HCC)

Rznomics Inc. (Seoul, South Korea private; specialty: RNA-based gene therapeutics)
FDA RMAT designation granted to RZ-001 for hepatocellular carcinoma
Trans-splicing ribozyme platform; replaces cancer-specific RNA with therapeutic RNA (hTERT-targeted; trans-ligates HSVtk-encoding sequence)
Prior designations: ODD (Feb 2024) + Fast Track (Feb 2025); now third FDA expedited-development designation in 27 months
Underlying clinical: AACR 2026 oral presentation 19 April 2026 — combination with atezolizumab + bevacizumab in TACE-refractory / TACE-ineligible HCC; 38.5% confirmed ORR / 46.2% unconfirmed ORR (RECIST v1.1)
Read-through: Korean origination + RMAT status positions Rznomics as a credible 2027/2028 ex-Asia out-licensing candidate; comparable structure to LegoChem Biosciences / Biocon ADC platform deals

Raynovent ZSP1601 Phase 2b MASH (China-origin)

Guangdong Raynovent Biotech Co., Ltd. (Guangzhou, China; private)
Phase 2b topline in metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis
64.9% response rate with first-in-class pan-PDE inhibitor ZSP1601
Mechanism: pan-phosphodiesterase inhibitor (PDE2-dominant; also PDE1A, PDE4B, PDE5A); raises intracellular cAMP → suppresses TNF-α; differentiated from THR-β + GLP-1 + FGF21 incumbent MASH classes
Phase 1b/2a precedent: published Nature Communications 2023 — dose-related LFC reduction up to 25.50% (100 mg BID arm) at 4 weeks
Read-through: third China-origin MASH asset to print credible Phase 2 data in 2026 (alongside CSPC ALK7-class assets and broader China MASH out-licensing momentum); cleanest disclosed pan-PDE MASH proof-of-concept globally; positions Raynovent as a 2026/2027 out-licensing candidate consistent with broader China-origin MASH licensing trend (Madrigal/CSPC Jul 2025; Madrigal/Ribo Feb 2026)

Kelun-Biotech / Merck (MSD) — sac-TMT 1L NSCLC sNDA accepted by NMPA

Kelun-Biotech Pharmaceutical Co., Ltd. (HKEX: 6990; Chengdu); MSD ex-Greater China rights via 2022/2023 ~$9B framework
NMPA CDE accepted sNDA for sacituzumab tirumotecan (sac-TMT / MK-2870) + pembrolizumab as 1L therapy in PD-L1 TPS ≥1% advanced NSCLC (EGFR/ALK-negative); priority review
Phase III OptiTROP-Lung05 basis; 5th sac-TMT indication accepted under NMPA priority review
Read-through: each new sac-TMT indication expands MSD's global royalty-bearing development program; reinforces W19 China-out-licensing track-record alongside GSK / SiranBio (Wed) and BeOne / Huahui (Wed Q1 disclosure)

Other Friday events (mechanical)

Cytokinetics (CYTK): $700M follow-on closes (priced 7 May; see Capital Markets section). Aficamten royalty implications already framed under ACACIA-HCM read-through.
Mobia Medical (MOBI): IPO trading debut on Nasdaq Global Select; commercial-stage neuro-recovery medical device.
KALA BIO (KALA): 1-for-50 reverse stock split effective; 929.5M → 18.6M sh; new CUSIP 483119301; Nasdaq compliance restoration; AI pivot via Researgency.ai (going-concern flag remains).
BioAge Labs (BIOA): R&D Day on NLRP3 inhibition; BGE-102 Phase 1 ≥85% median hsCRP reduction at 60–120 mg QD; Phase 2 ASCVD POC guided H2 2026. Read-through to CV-inflammation royalty/license lane.
Genelux (GNLX): Q1 release; cash $26.3M; OnPrime/GOG-3076 Phase 3 ovarian (Olvi-Vec) topline 2H 2026 on track.

Corporate Movements (Mon 4 May)

Viatris / Edwards CFO Swap

Movement	Detail
Resigning	Doretta Mistras, Viatris CFO (notice 1 May; 8-K 4 May)
Viatris interim	Paul Campbell (8 May); Mistras transitions through 22 May
Mistras at Edwards (EW)	CFO effective 29 May, succeeding Scott Ullem
Edwards comp	$925k base, 100% target bonus, $2.0M sign-on, $8.0M RSUs, $4.5M annual equity

Other

Suketu Upadhyay began as Incyte CFO 4 May (departed Vertex board 28 Apr)
Kyverna (KYTX): Nadia Dac appointed CCO
Passage Bio: 75% workforce reduction following FDA trial-design request
Jaguar Health (JAGX): Nasdaq deficiency post-1-for-35 reverse split
Knoa Pharma LLC (Purdue Pharma's $7.4B Chapter 11 nonprofit successor) began operations 1 May

The Weekly Term Sheet is published by Capital for Cures AG. Nothing in this publication constitutes investment advice or a recommendation to buy or sell any security. Royalty-rate ranges, milestone schedules, and specific deal terms are reconstructed from public filings, press releases, and investor materials; specific contractual terms not in the public domain are noted as such. Errors and omissions are the author's own. For corrections, queries, or republication requests, contact the editorial team via p05.org.